A spontaneous model of central neuropathic pain:syringomyelia in the Cavalier King Charles Spaniel by Thøfner, Maria Søndergaard
u n i ve r s i t y  o f  co pe n h ag e n  
A spontaneous model of central neuropathic pain





Publisher's PDF, also known as Version of record
Citation for published version (APA):
Thøfner, M. S. (2019). A spontaneous model of central neuropathic pain: syringomyelia in the Cavalier King
Charles Spaniel. DEPARTMENT OF VETERINARY CLINICAL SCIENCES FACULTY OF HEALTH AND
MEDICAL SCIENCES UNIVERSITY OF COPENHAGEN.
Download date: 10. Sep. 2020
A spontaneous model of central 
neuropathic pain 
– syringomyelia in the Cavalier King Charles Spaniel
PhD thesis 2019
Maria Søndergaard Thøfner
DEPARTMENT OF VETERINARY CLINICAL SCIENCES
FACULT Y OF HEALTH AND MEDICAL SCIENCES
UNIVERSIT Y OF COPENHAGEN
PHD THESIS 2019 · I S B N  9 7 8 - 8 7 - 7 2 0 9 - 2 7 8 - 2
M A R I A  S Ø N D E R G A A R D  T H Ø F N E R
A spontaneous model of central neuropathic pain




















odel of central neuropathic pain – syringom
yelia in the Cavalier King Charles Spaniel
u n i ve r s i t y  o f  co pe n h ag e n
fac u lt y  o f  h e a lt h  a n d  m e d i c a l  s c i e n c e s
A spontaneous model of central 
neuropathic pain 
– syringomyelia in the Cavalier King Charles Spaniel
PhD thesis 2019
Maria Søndergaard Thøfner
DEPARTMENT OF VETERINARY CLINICAL SCIENCES
FACULT Y OF HEALTH AND MEDICAL SCIENCES
UNIVERSIT Y OF COPENHAGEN
PHD THESIS 2019 · I S B N  9 7 8 - 8 7 - 7 2 0 9 - 2 7 8 - 2
M A R I A  S Ø N D E R G A A R D  T H Ø F N E R
A spontaneous model of central neuropathic pain




















odel of central neuropathic pain – syringom
yelia in the Cavalier King Charles Spaniel
u n i ve r s i t y  o f  co pe n h ag e n






































This  thesis  has  been  submitted  to  the  Graduate  School  of  Health  and  Medical  Sciences,  University  of 
Copenhagen, 31st of March 2019. 
 
Title:             A spontaneous model of central neuropathic pain ‐ syringomyelia in the Cavalier  
King Charles Spaniel 
 





Co‐supervisors:       Professor Merete Fredholm, DVSc, Department of Veterinary and Animal Sciences,  




Professor  Emeritus  Ole  Jannik  Bjerrum,  DMSc,  Department  of  Drug  Design  and 
Pharmacology, University of Copenhagen, Denmark 












                Quantification of Luca Løvhøj’s mechanical sensory threshold  















of  Health  and  Medical  Sciences,  University  of  Copenhagen,  Denmark.  The  thesis  is  based  on  research 









The  principal  supervisor  of  the  PhD  project  was  Professor  Mette  Berendt,  DVM,  PhD,  University  of 
Copenhagen. Co‐supervisors, both from Aarhus University were Professors Jens Randel Nyengaard, DMSc and 
Troels Staehelin Jensen, DMSc; as well as Professor Merete Fredholm, DVSc and Professor Emeritus Ole Jannik 











































your  engagement  in  the  project  and  for  being  a  role model with  high  professional  standards.  To Merete 


























































































CGRP      Calcitonin gene‐related peptide 
CKCS      Cavalier King Charles Spaniel 
C1M      Chiari‐1 malformation 
CM      Chiari‐like malformation 
CM‐SM    The Chiari‐like malformation ‐ syringomyelia complex in Cavalier King Charles Spaniels 
CNeP      Central neuropathic pain 
CSF       Cerebrospinal fluid  
DN4      Douleur Neuropathique 4 
DREZ      Dorsal root entry zone 
DRG      Dorsal root ganglion 
fT4       Free thyroxine, the metabolic active fraction of the thyroid hormone 
GABA      Gamma‐aminobutyric acid 
GEE      Generalised estimating equation 
GWAS     Genome‐wide association study 
IASP      International Association for the Study of Pain 
LANSS     The Leeds Assessment of Neuropathic Symptoms and Signs 
MRI      Magnetic resonance imaging 
MST      Mechanical sensory threshold 
MSTQ     Mechanical sensory threshold quantification 
NMDA    N‐methyl‐D‐aspartate 
NPS      The Neuropathic Pain Scale 
NPSI      The Neuropathic Pain Syndrome Inventory 
NRS      Numeric rating scale 
NSAID     Non‐steroidal anti‐inflammatory drug 
PAG      Periaqueductal grey 
PI        Principal investigator 
PGN      Pregabalin 
QST      Quantitative sensory test 
SP        Substance P 
STEP      Sensory threshold examination protocol 
T1W      T1‐weighted (MRI) 
T2W      T2‐weighted (MRI) 
T4        Thyroxine (tetraiodothyronine) 
TCA  Tricyclic antidepressant 
TRPV1  The capsaicin receptor ‐ one of six vanilloid transient receptor potential ion channels 
TSH      Thyroid‐stimulation hormone 
VAS      Visual Analogue Scale 













Spaniels  (CKCS).  Affected  dogs  present  with  physical  and  behavioural  indicators  of  discomfort  and  pain 
characterised  by  spontaneous  or  evoked  scratching,  hypersensitivity  to  touch  and  paroxysmal  pain 
manifestations with  vocalisation.  In  human  patients with  SSM,  90%  suffer  pain,  of  these  40%  experience 












SSM  in  families, eight symptomatic dogs  from different  litters were selected. The eight  litters  (34 siblings) 
comprised 17 asymptomatic and 17 symptomatic dogs. The incidence of symptomatic and asymptomatic dogs 
was converted to normal distributed mean  liabilities, and their standard deviation from the  threshold was 
used  to  estimate  the heritability  of  SSM. A high heritability  of  0.81 was  found.  This  finding  indicates  that 
genetics have a strong impact on the total phenotypic variance in the population. An association between the 
expression of symptoms and magnetic resonance imaging (MR)‐findings was investigated in the 34 littermates. 
Twenty‐two  dogs  underwent  clinical  characterisation  including  MRI.  The  diameter  of  the  syrinx  and  the 
syrinx/spinal cord ratio was significantly different between symptomatic and asymptomatic dogs (P<0.01). A 
significant association between the expression of symptoms and (1) syrinx diameter and (2) syrinx/spinal cord 
ratio was  confirmed.  Long‐term  outcome  in  symptomatic  and  asymptomatic  dogs was  assessed  in  31/34 









This  prospective  case‐control  study  investigated,  if  the  clinical  phenotype  is  associated  with  mechanical 




could  not  be  confirmed  that  the  clinical  phenotype  of  SSM  is  characterised  by  mechanical  threshold 
  10
alterations. Accordingly,  it  remains unknown whether  symptomatic dogs have altered mechanical  sensory 
thresholds 
 




were  affected  in  CKCS  with  SSM.  Spinal  cord  segments  C1‐C8  were  investigated  in  eight  cases  and  four 
controls. Seven of the eight included dogs with SSM expressed unilateral symptoms of CNeP. A stereological 
quantification  of  the  total  volume  of  the  spinal  cord  segments  C1‐C8  and  relevant  sub‐volumes  was 
undertaken.  Comparisons  of  the  total  mean  volumes  and  sub‐volumes  revealed  no  significant  difference 
between cases and controls. A significant volume loss of the dorsal horn laminae I‐III was found on the affected 










function  as  an  effective  treatment  of  syringomyelia‐related  pain  in  CKCS.  Thirteen  dogs  with  SSM  were 
included and randomised to treatment arm A (pregabalin ➝ placebo; n=5) or treatment arm B (placebo ➝ 
pregabalin;  n=8).  Treatment  periods were  of  25  days  duration,  segregated  by  a  48‐hour wash‐out  period 
before cross‐over. Outcome was number of scratching events during ten minutes of exercise at baseline and 
at  four  follow‐ups. Eleven dogs completed  the  trial. The effect of pregabalin was estimated  to be an 84% 
reduction from baseline in mean number of scratching events when compared to placebo (P<0.0001). Hence, 





SSM  constitute  a  promising  counterpart  to  the  experimental  animal  models  in  several  aspects:  the 
spontaneous development of disease, the slow progression over time and a diverse clinical phenotype. The 
histomorphological findings and the results of the clinical trial demonstrate the back‐ and forward translational 








Symptomatisk  syringomyeli  (SSM) er en  spontant  forekommende neurologisk  sygdom hos hunde af  racen 
Cavalier  King  Charles  spaniels  (CKCS).  Lidelsen  er  karakteriseret  ved  fysiske  og  adfærdsmæssige  tegn  på 
ubehag  og  smerte  udtrykt  ved  spontan  eller  udløst  kløe,  over‐følsomhed  for  berøring  og  anfaldsvise 
smerteudbrud med vokalisering. Smerte forekommer hos 90% af mennesker med SSM, heraf rapporterer 40% 
neuropatisk  smerte.  Forståelsen  for  udviklingen  af  syringomyeli  hos  både  mennesker  og  hunde  er 
ufuldstændig,  og  få  individer  opnår  en  tilfredsstillende  effekt  af  smertebehandling.  Udviklingen  af  nye, 
effektive  smertestillende  præparater  er  stagneret  primært  på  grund  af  en  mangel  på  eksperimentelle 








mulige  respondenter  svarede  123.  Nitten  symptomatiske  hunde  blev  identificeret  efter  et  bekræftende 
telefoninterview. Den  korrekte  klassificering  af  hunde  som  værende  symptomatiske  blev  bekræftet  i  74% 
(14/19)  af  hundene  ved  klinisk  undersøgelse.  Prævalens  af  SSM  blev  estimeret  til  15.4%  [9%,  22%]. 
Prævalensen  af  SSM  i  udvalgte  familier  blev  estimeret  efter  udvælgelse  af  otte  symptomatiske  hunde  fra 
forskellige kuld. De otte kuld (34 kuldsøskende) indbefattede 17 symptomatiske og 17 asymptomatiske hunde. 
Forekomsten  af  symptomatiske  og  asymptomatiske  hunde  blev  omdannet  til  gennemsnit  på  den 
standardiserede normalfordeling, og gennemsnittenes standardafvigelse fra tærskelværdien blev anvendt til 
at estimere heritabiliteten af SSM. En høj heritabilitet på 0.81 blev påvist. Dette fund indikerer, at genetiske 
faktorer  har  en  stor  indflydelse  på  den  totale  fænotypevarians  i  populationen.  Sammenhængen  mellem 
forekomsten  af  symptomer  og  fund  på  magnetisk  resonans  skanning  (MRI)  blev  undersøgt  i  de  34 
kuldsøskende. Toogtyve hunde blev undersøgt klinisk og fik foretaget en MR‐skanning. Der var en signifikant 
forskel i syrinx‐diameter og syrinx/rygmarvs‐ratio imellem symptomatisk og asymptomatiske hunde (P<0.01). 
Dermed  blev  sammenhængen  mellem  symptomer  og  (1)  syrinx‐diameter  og  (2)  syrinx/rygmarvs‐ratio 
bekræftet. Udviklingen af symptomer over tid blev undersøgt hos 31/34 kuldsøskende. Efter fem år var 93% 
(14/15)  af  de  asymptomatiske  hunde  fortsat  symptomfri,  mens  81%  af  de  symptomatiske  hunde  forblev 
















Studie  III:  Superficial  dorsal  horn  volume  loss  in  Cavalier  King  Charles  Spaniels  with  neuropathic  pain  and 
syringomyelia – a quantitative and qualitative histological characterisation of cervical spinal cord lesions. 
Denne design‐baserede stereologiske og histopatologiske karakterisering af rygmarvslæsioner blev foretaget 
med  det  formål  at  undersøge  om  syringomyeli  afficerer  én  eller  flere  specifikke  strukturelle  enheder  i 
rygmarven, som er involveret i nociception. Rygmarvssegmenterne C1‐C8 fra otte cases og fire kontroller blev 












Et  randomiseret, dobbelt‐blindet, placebokontrolleret overkrydsningsstudie blev udført  for  at  vurdere, om 
pregabalin kan fungere som en effektiv behandling af syringomyeli‐relateret smerte hos CKCS. Tretten hunde 
med  SSM  blev  inkluderet  og  randomiseret  til  behandlingsarm  A  (pregabalin  ➝  placebo;  n=5)  eller 
behandlingsarm B (placebo ➝ pregabalin; n=8). Behandlingsperioderne varede 25 dage og var adskilt af en 
48‐timers udvaskningsperiode før overkrydsning. Outcome‐variablen var antallet af kløe‐episoder i løbet af en 
ti  minutters  gåtur  målt  før  studie‐opstart  og  ved  fire  kontrolbesøg.  Elleve  hunde  gennemførte 





Denne  afhandling  giver  ny  information  om  neuropatisk  smerte  hos  CKCS  med  syringomyeli.  Det  er 
sandsynligvis uopnåeligt at udtrykke de præcise symptomer på neuropatisk smerte, som mennesker oplever, 
i  dyremodeller.  Ikke  desto  mindre  udgør  CKCS  med  SSM  en  lovende  pendant  til  de  eksperimentelle 
dyremodeller på flere punkter: den spontane udvikling af sygdom, den langsomme udvikling over tid og en 
uensartet klinisk fænotype. De histomorfologiske fund og resultatet af behandlingsstudiet viser potentialet for 







simplicity  and,  at  least  at  first  glance,  straightforwardly  understood.  We  imagine,  we  share  a  common 









Accordingly,  there  are  no measurable  biomarkers  of  pain. Human patients  suffering  pain  can  assess  their 
experiences of pain on predefined pain scales. In experimental pain models, pain is measured in terms of a 











American  university  hospital  outpatients  (Muir  et  al.  2004).  The  diverse  and  often  subtle  clinical  signs  of 
chronic pain that dogs express probably means that there is an inadequate recognition of veterinary patients 
with chronic pain. This may result in an underestimation of the presence of pain and its implications for the 






The  aetiologies  are  numerous.  The  pain  may  arise  as  a  consequence  of  functional  changes  in  the 




al. 2010). Syringomyelia‐related neuropathic pain  is  fundamentally different  from other  types of pain. The 
pathogenesis  is  not  fully  understood  and  the  pain  phenotype  is  very  diverse.  In  addition,  an  insufficient 













medical  needs,  the  overall  aim  of  this  thesis  is  to  investigate  if  the  CKCS with  syringomyelia  represent  a 
spontaneous model  of  central  neuropathic  pain.  The  specific  aims  and hypotheses  of  the  four  conducted 
studies are respectively: 
 










HA:   The  structural  spinal‐cord parenchymal  lesions  result  in  a  significant difference  in mechanical 
sensory  threshold  between  symptomatic  CKCS  with  syringomyelia  and  asymptomatic  CKCS 
without syringomyelia. 
 

















Neuropathic  pain  arises  as  a  consequence  of  functional,  biochemical  and  structural  changes  in  the 
somatosensory pathway. To understand these  functional changes, what  follows now  is an overview of  the 










threshold  mechanoreceptors.  Innocuous  thermal  inputs  are  detected  by  thermoreceptors.  Noxious 
mechanical, thermal and chemical stimuli are mediated through distinct subtypes of peripheral, polymodal 
nociceptors (Koch et al. 2018; Yam et al. 2018). A stimulus detected by a primary afferent’s peripheral terminal 










allows  them to  respond  to vibration and  light  touch. The nociceptive Aδ‐ and C‐fibres  respond  to noxious 
mechanical,  thermal  and  painful  stimuli.  Aδ‐fibres  are  medium‐sized,  thinly  myelinated  and  hence  their 








lamina  I  and  the  outer  layer  of  lamina  II  (lamina  IIO).  The  touch  and  tactile  stimuli with  low‐intensity  are 
mediated through low‐threshold Aβ‐ and C‐fibres. These low‐threshold, mechanosensitive fibres synapse with 








of  their  action  potentials.  A  normal  neuron  fires  ‘all‐or‐none’  action  potentials when  activated.  The WDR 
neurons fire graded action potentials; this characteristic enables them to grade their response depending on 
the  intensity  and  frequency  of  the  peripheral  stimulus.  When  WDR  neurons  are  subject  to  repetitive 
stimulation,  they  respond  by  exaggerating  their  firing‐rate.  If  the  repetitive  stimulation persists,  the WDR 
neurons’  membrane  become  increasingly  susceptible  to  the  afferent  input.  This  sustained,  partial 
depolarisation  is  also  known  as  ‘wind‐up’  (Voscopoulos  &  Lema  2010;  Pozek  et  al.  2016).  A  third 


















and  inhibitory  interneurons  and  terminals  of  other  descending  pathways.  A  battery  of  neurotransmitters, 
receptors  and  modulators  are  involved  in  this  complex  process.  Noradrenaline  released  by  descending 
efferents binds to ɑ‐2 receptors of spinal projection neurons. The result is either direct inhibition of primary 
afferent  transmitter  release  or  indirect  inhibition  through  acetylcholine  release  and  activation  of  primary 
afferent inhibitory muscarinic M2‐receptors. While serotonin is involved in both facilitation and inhibition, the 















Innocuous  and  noxious  peripheral  stimuli  are  mediated  through  sensory  Aβ‐,  Aδ‐  and  C‐fibres.  The  primary 























can be evoked by  innocuous or noxious  stimuli  (Gilron et  al.  2015; Colloca et  al.  2017).  Pain evoked by  a 
normally innocuous stimulus is designated as allodynia. Increased pain from a stimulus normally eliciting pain 













and  inhibition. The  inhibitory  / excitatory  imbalance can occur both  in  the peripheral and central nervous 









Kuner &  Flor  2016).  That  is  also  the  case  for  the different  roles  of  peripheral  and  central mechanisms  in 
neuropathic  pain.  Three  key  concepts  have  been  put  forward  to  explain  allodynia  and  hyperalgesia,  the 









The  cardinal  signs  of  inflammation,  calor,  dolor,  rubor,  tumor  and  function  laesa  are  results  of  the  local 
inflammatory response due to increased vascular permeability and peripheral oedema (Voscopoulos & Lema 





cord.  This  peripheral  sensitisation  is  a  physiological  consequence  of  the  original  tissue  injury.  It  serves  to 
protect the tissue from further damage and facilitate healing by avoiding contact with and use of the injured 























and  punctate  stimuli  (Benarroch  2016).  A  post‐synaptic  activation  of  the  N‐methyl‐D‐aspartate  (NMDA)‐
receptor occurs by release of glutamate. In turn, the NMDA‐receptor activation results in a cascade of pre‐ 
and postsynaptic  upregulation  of  receptor‐  and neurotransmitter  expression.  T‐type  calcium  channels  are 
activated,  and  an  increased  ɑ2δ‐subunit  expression  occurs.  The  ɑ2δ‐subunit‐upregulation  facilitates  an 
elevation  of  intracellular  Ca2+,  and  a  concomitant  upregulation  of  sodium  channels  causes  long‐term 
potentiation and amplification of peripheral  inputs (Prescott et al. 2014; Kuner & Flor 2016; Alles & Smith 







descending  inhibition  ‐  characterised  by  attenuated  noradrenergic  inhibition  and  enhanced  serotonin 
signalling  ‐ may contribute  to central gain and maintenance of  the pain  state  (von Hehn et al. 2012). The 
  20
peripheral and central mechanism may become entangled into a vicious circle; recent findings indicate that 









assessment  should  be  conducted  to  confirm  the  presence  or  absence  of  specific  sensory  abnormalities, 
allodynia and hyperalgesia. In the case of pain and sensory abnormalities of unknown aetiology, an objective 

















Evaluation  of  the  somatosensory  profile  includes  assessment  of  the  various  sensory  modalities  using 
mechanical  and  thermal  stimuli  (Cruccu  &  Truini  2009).  The  evaluation  can  be  based  on  an  all‐or‐non‐
response, a graded response or by a comparison of sensations between a test and reference site. Table 1 
presents  an  overview  of  some  of  the  qualitative  and  quantitative  assessment  tools  that  are  available. 
Qualitative assessment is undertaken in the clinical setting, whereas the experimental situation often requires 













































is  the most  prevalent  (Tubbs  2015;  Klekamp 2018).  The  in  vivo  diagnosis  requires MRI  (Figure  2). Due  to 
inconsistencies in the definition of syringomyelia, the prevalence in the general population is unknown but 
may be as low as 8.2‐8.4 per 100.000 in Western countries (Brewis et al. 1966; Brickell et al. 2006; Kahn et al. 






















Despite  extensive  clinical  and  experimental  research  including  theoretical  and  mechanical  models,  the 
underlying  pathogenesis  of  syrinx  formation  remains  unknown  (Greitz  2006;  Koyanagi  &  Houkin  2010; 
Linninger et al. 2016). With emerging novel techniques enabling visualisation of CSF flow dynamics, the most 
recent  suggested  pathogeneses  and  subsequent  classification  focus  either  on  the  alterations  in  CSF  flow 
dynamics or on compromised extracellular fluid absorption due to obstructions in the atlanto‐occipital space 

















al.  2000;  Ducreux  et  al.  2006;  Hatem  et  al.  2010).  Over  time  patients  may  develop  concomitant  motor‐ 
impairment,  segmental  weakness,  muscle  atrophy  and  autonomic  dysfunction.  The  clinical‐neurological 











localised  to  the  cervicodorsal  dermatomes with  a  uni‐  or  bilateral,  symmetric  or  asymmetric  distribution 
(Cohodarevic et al. 2000; Ducreux et al. 2006; Hatem et al. 2010). Coughing and sneezing, physical activity and 
posture  change,  stress  and  barometric  fluctuations  can  intensify  the  pain  (Cohodarevic  et  al.  2000).  The 
neuropathic  pain  is  either  spontaneous  ongoing  (stimulus‐independent),  paroxysmal  or  evoked.  Common 
descriptors are  radicular, burning, dull, aching, pressing,  throbbing or stretching. The abnormal sensations 








the  publication  by  Milhorat  et  al.  (2001).  Based  on  the  pathological  findings  and  MRI‐confirmed 
clinicopathological  correlates  the  authors  classify  syringomyelia  as  1)  communicating  syringomyelia 
characterised  by  central  canal  dilations  communicating  with  the  4th  ventricle;  2)  non‐communicating 
syringomyelia  characterised  by  either  primary  parenchymal  cavitations  secondary  to  spinal  cord  trauma, 























spinal  cord  dorsal  horns  in  ten  patients with  syringomyelia  and  ten  patients without  neurological  disease 












As  in humans,  syringomyelia develops secondary  to  inflammation,  trauma, obstruction of CSF  flow due  to 












incidental  finding  (Lu  et  al.  2003;  Couturier  et  al.  2008).  In  succeeding  years,  an  increased  number  of 
symptomatic cases triggered an awareness of potential breeding implications in this very popular breed. In 
response, MRI  screening  for  breeding  purposes was  initiated  in  the United  Kingdom  in  2006  (Cappello & 
Rusbridge 2007). 
 
Estimates  of  asymptomatic  syringomyelia  are  based  on  screening  MRI  for  breeding  purposes.  In  a 
retrospective  assessment  of  555  pre‐breeding  screening MRIs  of  CKCS  from  the United  Kingdom  and  the 
Netherlands,  the  prevalence  of  asymptomatic  syringomyelia  of  46%  has  been  reported  based  on  owner‐
assessed absence of clinical signs (Parker et al. 2011). The occurrence of asymptomatic syringomyelia increases 
with age; from 25% in dogs up to 12 months of age to 70% in dogs ≥ six years of age. CM is found in more than 






















bilateral and  is directed at  the head, ears, neck, shoulders, axillae, chest or ventral abdomen. Factors  that 
aggravate the scratching are collars and harnesses, bathing in warm or cold water, excitement and stressful 
situations.  The  intensity  of  scratching may  increase  in  intact  bitches  during  oestrus  (Plessas  et  al.  2012). 





















syrinx  diameter  relative  to  that  of  the  spinal  cord  and  to  the  lack  of  syrinx  symmetry.  The  greater  the 
syrinx/spinal  cord  ratio, and  the more asymmetrical distribution directed  towards  the dorsal horns on  the 
transverse images, the more severe are the symptoms and signs of pain (Rusbridge et al. 2007).  
 
The  implication  of  CM  is  identified  on MRI  as  cerebellar  indention or  partial  cerebellar  herniation  into  or 
through the foramen magnum (Cappello & Rusbridge 2007). A smaller ratio of the caudal fossa volume relative 
to  the  total  cranial  cavity  volume  is  associated with  the  presence  of  clinical  signs.  In  addition  to  CM and 











T1W  sagittal  (a  and b)  and  transverse  (c) MRI  of  a  21‐months  old  spayed  female  Cavalier  King  Charles  Spaniel with 
lateralised scratching directed at the right (R) side of her neck. MRI‐findings were Chiari‐like malformation and partial 
cerebellar  herniation  indicated  by  a  red  asterix  in  (a)  and  asymmetric  (right)  cervical  syringomyelia  characterised  by 
hypointense (black) appearance of a fluid‐filled cavity in (b) from the cranial level of the spinal cord’s segment C1 to the 
cranial  level of C5. The height of  the syrinx was 0.47 cm, and the syrinx/spinal cord  ratio was 0.66 measured on  the 























































associated  clinical  signs  in  CKCS:  NSAIDs,  corticosteroids,  diuretics,  proton  pump  inhibitors,  opioids, 
gabapentinoids and amitriptyline  (Rusbridge 2005; Rusbridge & Jeffery 2008; Plessas et al. 2012). None of 
these suggested compounds have proven sufficient effect in the reduction of clinical signs of neuropathic pain. 




Forms  of  surgical  management,  including  foramen  magnum  decompression  and  syringo‐subarachnoid 
shunting, have all been trialled to prevent syrinx progression and to reduce clinical signs (Dewey et al. 2004; 
Vermeersch  et  al.  2004; Motta &  Skerritt  2012).  Post‐operative  outcome  assessment  varies  between  the 
studies. Overall,  initial  improvement  in clinical status  is seen  in up to 80% of cases. However,  in  long‐term 







(Driver  et  al.  2013).  In  addition,  an  insufficient  response  to  treatment  is  seen  in  both  human  and  canine 
















































An  overview of  the  119  dogs  that  underwent  clinical  characterisation  from 2013  ‐  2018.  Red  letters  in  parentheses 

























After history uptake,  a  standardised  clinical  and neurological examination was undertaken. Blood  samples 
were collected for haematology and a biochemical profile. The clinical characterisation of the dogs in Studies 
II‐IV additionally included otoscopy and microscopy of cerumen, urinalyses after cystocentesis and a thyroid 










A  in  Paper  II,  page  67.  The MR  images were  assessed  immediately  after  they were  obtained by  the  PI.  A 










A  cross‐sectional  study  was  undertaken  to  estimate  the  prevalence  of  symptomatic  syringomyelia  in  the 
Danish  population.  The  study population  consisted  of  all  CKCS  (n=240)  born  and  registered  in  the Danish 
Kennel  Club  in  2001.  Consequently,  the  dogs  were  all  six  years  of  age  when  the  study  was  undertaken. 
Screening  questionnaires  addressing  clinical  signs  of  syringomyelia were mailed  to  the  240  owners.  One‐

































34  littermates  identified  in  the  prevalence‐  and  heritability  study.  Twenty‐two  dogs  underwent  clinical 
characterisation including MRI. Clinically, 13 dogs were symptomatic and nine were asymptomatic. On MRI, 






and asymptomatic dogs. The hypothesised association between  the expression of  symptoms and  (1)  syrinx 
diameter and (2) syrinx / spinal cord ratio was confirmed (P<0.01 for both comparisons).  
 
The  frequent  occurrence  of  syringomyelia  in  middle‐aged,  asymptomatic  dogs  reported  in  Study  I  was 


























Regarding  the  22  littermates  that  underwent  clinical  characterisation  including  MRI  in  2007,  follow‐up 
information  could  be  obtained  on  20/22  dogs.  Eleven  of  these  dogs were  identified  as  symptomatic  and 
syringomyelia‐positive  in 2007.  In that year, eight of the nine asymptomatic dogs were also syringomyelia‐
positive.  The  owners  reported  that  10/11  (91%)  symptomatic,  syringomyelia‐affected  dogs  remained 
symptomatic;  meanwhile,  8/9  (89%)  asymptomatic  dogs  had  remained  asymptomatic.  Only  one 
asymptomatic, syringomyelia‐affected dog developed symptoms of syringomyelia during the five‐year period. 
 
The  owner‐assessed  static  clinical  phenotype  was  later  confirmed  in  54  CKCS  (16  symptomatic  and  38 
asymptomatic) by Cerda‐Gonzales et al. The majority (68%) of asymptomatic dogs remained asymptomatic, 
and most (88%) symptomatic dogs remained symptomatic; progression of clinical signs was seen in 56% of 
symptomatic dogs < 36 months after MRI. The symptoms  improved with medical  treatment  in 2/16 (13%) 
symptomatic dogs. Three of these 54 CKCS (6%) had been euthanised due to myelopathy or signs of clinical 



























and mechanical hyperalgesia have been  reported as  frequently  occurring  sensory abnormalities  in human 











dogs’  reaction  to  cutaneous  stimulation  with monofilaments  (Touch  Test®  Sensory  Evaluators).  The MST 





























differences were  found between  cases  and  control when  comparing  the  initial MST with  the MST on  the 
contralateral side of the neck. Comparisons of the mean MST between dogs with symmetric and asymmetric 






















In  2017,  a  sensory  threshold  examination  protocol  (STEP)  was  developed  and  an  initial  validation  was 
undertaken in 25 healthy dogs of different sizes and ages to enable subsequent phenotyping of canine pain 
syndromes (Sanchis‐Mora et al. 2017). The tactile and mechanical thresholds were quantified with von Frey’s 





























and  functional  consequences  of  the  central  nervous  system  lesions  are  poorly  understood  as  are  their 
relationship  to  the  symptoms of CNeP.  For  these  reasons,  a design‐based  stereological quantification and 






































on  statistics  and  stochastic  geometry  and  uses  well‐defined  sampling  techniques.  In  Study  III,  systematic 










































































with  syringomyelia.  However, whether  the  symptoms  are  a  consequence  of  primary  deafferentation with 







syringomyelia‐affected  CKCS  are  indicators  of  pain  (Rusbridge  et  al.  2006;  Rusbridge  &  Jeffery  2008; 
Rutherford  et  al.  2012;  Sanchis‐Mora  et  al.  2016;  Cockburn  et  al.  2018;  Hechler  &  Moore  2018).  The 
euthanasia‐rate of symptomatic CKCS with syringomyelia is high due to an insufficient response to treatment. 























variable,  it would be natural  to use a Poisson distribution; yet,  to account  for a possible overdispersion, a 





































as  a  measurable,  indirect  biomarker  of  pain.  Despite  the  laborious  assessment  of  video‐recordings,  the 
outcome measure was easily quantified. In addition, the videos were used for a more detailed mapping of the 
individual dog’s scratching pattern, both with regard to the presence or absence of ‘phantom scratching’ and 
the  anatomical  area  to  which  the  scratching  was  directed.  The  dogs’  scratching  profile  changed  during 
treatment with PGN. At baseline,  eight dogs had one or more  ‘phantom scratch’  episodes during  the  ten 
minutes of outcome assessment. The phantom scratch stopped in 7/8 dogs during treatment with PGN. In 
addition to the scratching as a physical  indicator of discomfort,  the dogs’ behavioural  indicators of pain  in 
terms of vocalisation when scratching ceased in five individuals (100%) during treatment with PGN compared 
to baseline. These behavioral indicators of pain are quantifiable outcome measures that can be used to assess 




















aged CKCS  is  static.  It could not be confirmed that  the clinical phenotype of symptomatic syringomyelia  is 
characterised  by  mechanical  threshold  alterations.  The  study  on  histomorphology  has  demonstrated  a 
significant loss of dorsal horn grey matter and DREZ degeneration associated with clinical signs. Finally, PGN 
has been found effective in the reduction of clinical signs of neuropathic pain in the dogs. Altogether, these 
findings  demonstrate  several  comparative  aspects  to  human  symptomatic  syringomyelia.  However,  the 
functional, biochemical and structural causes of neuropathic pain in human and canine syringomyelia remain 
inadequately understood. Despite extensive preclinical research, there is a lack of experimental animal models 















et  al.  2004;  Hayes  et  al.  2010;  McGuinness  et  al.  2013;  Ives  et  al.  2015).  These  two  comorbidities  are 
confounders, introducing uncertainty about the actual explanation of the symptoms, especially facial rubbing 
and  scratching  directed  toward  the  ears,  sleep  disturbances  and  the  aberrant  behaviour  designated  ‘fly 
catching’ (Rusbridge & Jeffery 2008). In comparison, sleep disturbances are also a feature of the human C1M 
phenotype  as  are  different  types  of  headaches,  visual  and  auditory  disturbances  (Milhorat  et  al.  1999). 
Nevertheless, it remains uncertain whether CM and otitis media with effusion contribute to the overall clinical 
phenotype  in  symptomatic  CKCS.  A  definitive  diagnosis  of  CNeP  in  dogs  cannot  be  confirmed  due  to  the 
inherent lack of verbal communication. However, the author of this thesis advocates that a strong tentative 











body  area  as  indicated  on  the  scratch‐  and  pain‐map.  The  reported  findings  of  this  study  show  that  the 












































The  Venn  diagram  illustrates  the  criteria  that  should  be met  to  define  a well‐characterised  CKCS with  the  tentative 












an  intravascular,  laser  beam‐induced  photochemical  activation  of  the  photosensitising  dye  erythrosine  B. 
Demyelination  pain  in  multiple  sclerosis  is  modelled  by  experimental  induction  of  viral  or  autoimmune 
encephalomyelitis (Kumar et al. 2018).   
 
Despite  attempts  to  refine  such models,  few mimic  the  clinically  relevant  human  neuropathic  phenotype 
(Klinck et al. 2017). Most of these models represent neuropathological changes during the acute onset of pain 
(Yezierski & Hansson 2018). The models enable in vivo studies of the structural and functional consequences 
of  the  inflicted  nervous  system  lesion.  The  lesions  inflicted  on  the  nervous  system  may  result  in 
hypersensitivity. This hypersensitivity  is assessed by applying standardised mechanical and thermal stimuli. 
The endpoint is an evoked limb withdrawal. Hence, the hypersensitivity is characterised by increased response 
or  lowered  thresholds  to  the  stimuli.  This  reflex‐behaviour  is  translated  into  the  complex  clinical 
manifestations of neuropathic pain in humans, who are experiencing allodynia and hyperalgesia (Rice et al. 








































































 Express  measurable,  non‐evoked  efficacy  parameters  that  are  clinically  relevant  and  transferable,  to 













Chiari‐malformation  serves  as  an  aetiological  explanation  for  the  development  of  syringomyelia  in  both 
species. Cerebellar herniation in dogs and the caudal descent of cerebellar tonsils  in humans may result  in 











sensory assessment. This would enable  the desiderated classification and stratification  into  representative 
subgroups with specific sensory profiles as proposed by Rice et al. (2018). Despite the attempt to quantify the 
dogs’ MST in Study II, it was not possible to demonstrate conclusively whether symptomatic dogs have altered 




cannot  replace  a  thorough  history  uptake  and  clinical  examination  (Hunt  et  al.  2019).  Hence  it  remains 
unproven whether quantitative sensory assessment can be  implemented  in  the clinical characterisation of 
symptomatic CKCS with syringomyelia. 
 





therapeutic  action  of  PGN  in  neuropathic  pain  is  incompletely  understood  (Alles  &  Smith  2018), 
gabapentinoids are first‐line recommendations for treating human neuropathic pain (Finnerup et al. 2015). 












and  a  diverse  clinical  phenotype.  In  conclusion,  the  author  of  this  thesis  proposes  that  the  CKCS  with 








In‐depth  quantitative  and  histopathological  assessment  can  provide  novel  information  about  the  causal 
relationship  between  syringomyelia  and  neuropathic  pain  at  the  cellular  and molecular  level.  It would  be 
relevant to investigate whether excitotoxic neuronal necrosis or apoptosis is involved in grey matter loss. This 
can be done by quantification of immunolabelled sub‐populations of GABAergic and glycinergic dorsal horn 





quantitative  microscopic  investigations  of  spinal  cord  tissue  labelled  for  microglia  cells  (IBA1)  and 






future  hypotheses.  There  is  a  potential  for  identifying  one  or  more  candidate  genes  associated  with 
symptomatic syringomyelia in the GWAS briefly mentioned on page 30. This in turn offers a future back‐ and 
forward  translational  potential.  The  back‐translation  would  imply  genetical  manipulation  of  rodents. 
Experimental  genetical  modification  of  rodents  may  enable  spontaneous  development  of  disease. 
Investigation of the aethiopathogenesis and of the resultant phenotype ‐ including the structural, functional, 
cellular  and  molecular  consequences  of  syrinx  formation  ‐  may  identify  new  potential  targets  for  drug 








Development  and  subsequent  validation  of  the  extended  symptom  profile  assessment  tools  will  enable 

















with  symptomatic  syringomyelia  as  a  spontaneous model  of  central  neuropathic  pain.  It  was  shown  that 
symptomatic syringomyelia occurs in the breed with a prevalence of 15%. The heritability is high, suggesting 
a  strong  genetic  impact  on  the  clinical  phenotype.  The  hypothesized  alteration  in  mechanical  sensory 
threshold could not be confirmed as a descriptor of  the clinical phenotype. An association was confirmed 
between  the expression of  symptoms and  (1)  syrinx diameter and (2)  syrinx  /  spinal  cord  ratio, as was an 
association between a significant  loss of dorsal horn grey matter and dorsal root entry zone degeneration. 

























Prevalence  and  heritability  of  syringomyelia  in  Cavalier  King  Charles  Spaniels  and  long‐term  outcome  in 
symptomatic and asymptomatic littermates 
 
Maria  Søndergaard  Thøfner,  Camilla  Løkke  Stougaard,  Ulrik  Westrup,  Alexandra  Madry,  Christina  Strand 










Prevalence and Heritabil ity of Symptomatic Syringomyelia
in Cavalier King Charles Spaniels and Long-term Outcome
in Symptomatic and Asymptomatic Littermates
M.S. Thøfner, C.L. Stougaard, U. Westrup, A.A. Madry, C.S. Knudsen, H. Berg, C.S.E. Jensen,
R.M.L. Handby, H. Gredal, M. Fredholm, and M. Berendt
Background: Syringomyelia (SM) is common in the Cavalier King Charles Spaniel (CKCS). Dogs with syringes express
clinical signs or might be clinically silent.
Objectives: To investigate the prevalence and heritability of symptomatic SM, the association between clinical signs
and magnetic resonance imaging (MRI) findings, and long-term outcome.
Animals: All CKCS registered in the Danish Kennel Club in 2001 (n = 240).
Methods: A cross-sectional questionnaire-based prevalence study validated by telephone interviews and clinically inves-
tigated clinical signs of SM. Dogs were 6 years at the time of investigation. A prospective observational litter study includ-
ing clinical investigations, MRI and 5-year follow-up of symptomatic and asymptomatic siblings. Heritability was
estimated based on the scale of liability in the study population and litter cohort.
Results: The cross-sectional study estimated a prevalence of symptomatic SM at 15.4% in the population. Thirteen
symptomatic and 9 asymptomatic siblings participated in the litter study. Spinal cord syringes were confirmed in 21 of 22
littermates (95%). Syrinx diameter and mean syrinx : spinal cord ratio were significantly correlated with clinical signs
(P < .01). Estimated heritability of symptomatic SM was 0.81. Symptomatic SM motivated euthanasia in 20%. Dogs with
syringes, which expressed no clinical signs at the age of 6, remained asymptomatic in 14/15 cases (93%).
Conclusions and Clinical Importance: The prevalence of symptomatic SM is high and genetics have a high impact on
clinical disease expression. Further investigations of factors influencing the outbreak threshold of clinical signs of SM are
desirable.
Key words: Chiari-like malformation; Dog; Epidemiologic; Genetics; Magnetic resonance imaging.
Syringomyelia (SM) is a neurologic condition occur-ring in a hereditary form in the Cavalier King
Charles Spaniel (CKCS), the Griffon Bruxellois, in
other toy brachycephalic breeds as well as in
humans.1–4 The prevalence of SM in the CKCS has
not been estimated because of a lack of epidemiologic
studies investigating larger populations of dogs. SM is
characterized by the development of fluid-filled cavities
(syringes) within the spinal cord parenchyma and is
associated with Chiari I malformation in humans and
Chiari-like malformation (CM) in the CKCS.2,5–11 The
pathophysiology of CM involves a decreased caudal
fossa volume with overcrowding of the craniocervical
junction and caudal descend of the cerebellum into or
through the foramen magnum.5–15 The pathogenesis of
syrinx formation and the association between CM and
SM is not fully understood, but it is believed that a
multifactorial etiology including a local obstruction of
the subarachnoidal space and abnormal cerebrospinal
fluid dynamics are involved.5,10,12,16–19 Syringes are
predominantly found in the cervical region of the
spinal cord, but can form in multiple locations.20
In humans, the SM-associated damage to nocicep-
tive and other sensory pathways of the spinal cord,
causes pain to be a prominent feature in 50–90% of
adult patients.9,21,22 Other common clinical characteris-
tics in humans with SM include dermatomal patterns
of mixed loss of thermal sensitivity and paradoxical
association of hypersensitivity as well as trophic
changes with hyperhidrosis, glossy skin, coldness, and
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CKCS Cavalier King Charles Spaniel
CM chiari-like malformation
DICOM digital imaging and communications in medicine
DKC Danish Kennel Club
DVCAS Department of Veterinary Clinical and Animal
Sciences
FOV field of view
MRI magnetic resonance imaging
NEX number of excitations
NSAIDs nonsteroidal anti-inflammatory drugs
OME otitis media with effusion
SE spin echo
SM syringomyelia
T1 and T2W T1 and T2 weighted
TE time to echo
TR time to repeat
TSE turbo spin echo




paleness in humans.9,23 Dogs with SM display charac-
teristic behaviors, such as phantom scratching, unwill-
ingness to be touched or groomed in the head and
neck region, and in severe cases, paroxysmal pain
manifestations with vocalization, intense scratching,
rubbing, and circling on the floor. In dogs with SM,
these behaviors have been associated with pain.16,24–26
CKCS with a magnetic resonance imaging (MRI)-con-
firmed syrinx might be asymptomatic.21 In symptom-
atic CKCS, a wide syrinx diameter and asymmetric
distribution of the syrinx affecting the dorsal horn are
strong predictors of pain.25,27 Middle ear effusion (hy-
perintense material within the tympanic bulla probably
analogous to otitis media with effusion [OME] in
humans) is often present in the CKCS and may be
detected on T2-weighted MRI scans.28–30 The inci-
dence of OME in CKCS has been estimated to 32–
54%.28–31 It has been debated if some of the behaviors
associated with pain in CKCS could be related to
OME, but this however remains controversial.28,29,32,33
The heritability of SM has been estimated to be 0.37
based on MRI-confirmed syrinx findings in a cohort of
384 CKCS, whereas the heritability of symptomatic
SM has not previously been investigated.1
The aim of this study was to estimate the prevalence
and heritability of symptomatic SM in Danish CKCS.
Furthermore, to investigate the association between
clinical signs and MRI findings and report long-term
outcome in a CKCS litter cohort including symptom-
atic and asymptomatic siblings.
Materials and Methods
The study was initiated in 2007, finalized in 2012, and con-
ducted at the Department of Veterinary Clinical and Animal Sci-
ences (DVCAS), University of Copenhagen, Denmark. The study
population consisted of all CKCS born and registered in the
Danish Kennel Club (DKC) in 2001. The DKC register lists dogs
chronologically by date of registration, and to obtain a DKC
studbook, dogs must be registered no later than 3 weeks after
birth. The study was conducted in 3 phases.
Definitions
In this paper, the terms “symptomatic” and “asymptomatic”
have been chosen for simplicity sake although the authors
acknowledge that “symptomatic” is a subjective term inappropri-
ate for animals. “Symptomatic” is here defined as being indica-
tive of a specific disease (in this paper, the expression of clinical
signs of SM).
Phase I—Prevalence Study
A cross-sectional design was used to estimate the prevalence
of symptomatic SM. The study investigated clinical signs of SM
in the study population (n = 240). Dogs born in 2001 (>6 years
old) were chosen to secure that clinical signs of SM, if any,
would have had their debut at the time of investigation. The first
contact to the owners was established with a mailed letter distrib-
uted by the DKC. A short introduction of the investigation was
accompanied by an invitation to answer an enclosed screening
questionnaire with dichotomous alternative questions along with
a semiopen component in which comments could be stated. The
questions addressed the following clinical signs indicating SM:
unilateral/bilateral episodic scratching of the head/neck region,
phantom scratching of the head/neck region (the paw does not
touch the skin), reluctance to tolerate touching and/or grooming
of the head/neck region and/or resists wearing a collar. Signs are
worsened if the dog becomes exited, agitated or both, and signs,
which may be interpreted as pain often associated with the neck
region.10,34 The owners were asked to return their answers to the
DKC in an enclosed stamped envelope along with a written con-
sent confirming their participation and providing contact infor-
mation. Owners of dogs expressing at least one of the signs
listed, or who reported other clinical signs that could raise a sus-
picion of SM, were subsequently contacted by phone by the
investigators and enrolled in an interview. An extended standard-
ized questionnaire was used to provide further information and
validate the answers given in the screening questionnaire. The
telephone interview was performed by 2 investigators (CSEJ and
RMLH), supervised by 2 veterinary neurologists (HG and MB),
and the answers were subsequently scrutinized in collaboration
with a senior veterinary neurologist (MB). Dogs qualifying as
suspected symptomatic SM cases after validating telephone inter-
view were invited to participate in a clinical investigation at the
DVCAS Companion Animal University Hospital, including clini-
cal and neurologic examination and standard hematology, bio-
chemical, and thyroid profiles. Based on the definition of
“symptomatic” as being indicative of a specific disease (in this
case SM),35 a final evaluation procedure served to define (clinical)
symptomatic SM cases. The evaluation procedure included the
clinical signs reported by the owners subsequently confirmed by
the investigators and supported by the results of the clinical
investigation (focused on excluding possible differential
diagnosis).
Phase II—Litter Cohort Study
Eight litters were selected for further investigation of the asso-
ciation between clinical signs and MRI findings, based on pedi-
gree information and the criteria that at least 1 sibling had been
identified as a symptomatic SM case in the prevalence study. The
owners were contacted by phone and interviewed using an
extended standardized questionnaire addressing signs of SM to
report the clinical status of the dogs at the time of inclusion. All
dogs were invited to participate in the clinical investigation
including an oral investigator-owner interview, clinical and neu-
rologic examination, standard hematology, biochemical and thy-
roid profiles, and MRI of the brain and cervical spinal cord (C1–
T1). Dogs presenting with a heart murmur were further evaluated
with ECG and echocardiography.
Magnetic resonance imaging scans were performed using a 0.2
Tesla Esaote Vet-scan. The standardized protocol included T1-
weighted sagittal images of the neurocranium and cervical spinal
cord (C1–C3) (T1-spin echo [SE] with a field of view [FOV] of
14 cm, time to echo [TE] of 18 milliseconds, time to repeat [TR]
of 480–560 milliseconds, slice thickness 4 mm, a slice gap of
0.4 mm, and a number of excitations [NEX] of 3), T1-weighted
transverse SE sequences (FOV: 14 cm, TE: 18 milliseconds, TR:
930 milliseconds, slice thickness 5 mm, slice gap: 0.5 mm and
NEX: 3) of the neurocranium, T2-weighted sagittal sequences
(high resolution turbo spin echo [TSE], FOV 14 cm, TE: 80 milli-
seconds, TR: 2,800 milliseconds, slice thickness 4 mm, a slice gap
of 0.4 mm and NEX: 2) and T2-weighted transverse TSE
sequences (FOV 14 cm, TE: 80 milliseconds, TR: 2,800–
2,820 milliseconds, slice thickness 5 mm, a slice gap of 0.5 mm
and NEX: 2) of the neurocranium and cervical spinal cord (C1–
C3). T1 and T2 matrix: 256 9 256. The dogs were placed in ster-
nal recumbency, and the total examination time per patient was
75 minutes. Scans were transferred to the web-based DICOM




image viewing system RemoteEye,a blinded and subsequently
evaluated individually by 2 investigators (CSK & HB) and addi-
tionally by an experienced veterinary radiologist (UW).
T2 weighted images were used for syrinx measurements. A syr-
inx was defined as a fluid-filled cavity in the parenchyma with a
diameter ≥2 mm within the spinal cord. A presyrinx was defined
as edema in the spinal cord with a lesion diameter <2 mm with
or without central canal dilatation. A SM-positive case was
defined as a CKCS with a MRI-confirmed syrinx. Descriptive
data included syrinx diameter, cranial limit of the syrinx, distri-
bution of the syrinx (symmetric or asymmetric), and spinal cord
diameter. The syrinx : spinal cord ratio was calculated. If more
than 1 syrinx was detected, only the largest was used in the cal-
culations. The hypothesis of no association between the expres-
sion of clinical signs and the presence of a syrinx was tested
using Fisher’s exact test. The hypotheses of no association
between the expression of clinical signs and (1) syrinx diameter
and (2) syrinx : spinal cord ratio were tested using Student’s t-
tests. Data were analyzed by the statistical software in Excel,b
P < .05 was considered significant. It was recorded if CM, find-
ings consistent with otitis media with effusion (OME), or both
were present. CM was diagnosed when cerebellar indentation
caused by the supraoccipital bone with or without cerebellar her-
niation into or through the foramen magnum was identified. In
addition, it was recorded if the investigators initiated treatment
after the clinical and MRI investigations. In 2007, the treatment
used would typically be NSAIDs and/or furosemide (Furixc)
alone or in combination and in grave cases, furosemide and pred-
nisolone (Prednisolon DAKc).
Estimation of Heritability. The scale of liability (standard devi-
ation from threshold) in the 2 populations described in phase I
and II were used for the estimation of heritability according to
methods described for threshold characters.36 The applet avail-
able at http://www.ihh.kvl.dk/htm/kc/popgen/genetik/applets/
heritt.htm was used for the calculations.
Phase III—5-year Follow-up (2012)
A follow-up telephone interview was conducted in autumn
2012 with the purpose of investigating long-term outcome for the
now 11-year-old siblings participating in the 2007 litter cohort.
The telephone interview was performed by 1 investigator (CLS)
and supervised by a senior veterinary neurologist (MB) to secure
a standardized interview. A standardized questionnaire was used
to collect data regarding the status of the dogs including infor-
mation addressing alive/deceased, possible clinical signs, possible
progression or remission of clinical signs, development of new
clinical signs since 2007, treatment, and for deceased dogs, time
and cause of death.
Results
Phase I—Prevalence Study
Of 240 owners contacted by mail, 134 responded,
giving a response rate of 56% (Fig 1A). Eleven
responders were excluded (6 because the dogs were
euthanized before the age of 3, and 5 dogs where ques-
tionnaires were returned incomplete), leaving 123 dogs
(61 females and 62 males) to be included in the investi-
gation. Nineteen owners reported 1 or more clinical
signs of SM in their dogs (positive responders),
whereas 104 owners reported that their dog expressed
no clinical signs of SM (negative responders). After
the subsequent telephone interview and validation pro-
cedure, the 19 dogs (positive responders) were
categorized as suspected symptomatic SM cases. Four-
teen owners agreed to let their dogs participate in the
clinical investigation, which revealed no other diagno-
sis than SM, which could explain the signs expressed,
by the dogs. Five dogs did not participate in the clini-
cal investigation, but were evaluated to be symptom-
atic SM cases based on the expression of multiple
signs known to be associated with SM,16,19,24,37 and
where the owners reported that there had been no clin-
ical findings related to possible differential diagnosis
such as eg, skin disease, ear infection, etc. Thus, based
on the clinical signs reported and confirmed by the
investigators, and the results of the clinical investiga-
tion, 19 dogs (11 females and 8 males) were finally
included as symptomatic SM cases. The estimated
prevalence of symptomatic SM in 6-year-old Danish
CKCS born in 2001 was 15.4% (19/123), CI0.95 [9; 22].
Phase II—Litter Cohort Study
Eight litters were selected for further investigation
based on the criteria that at least 1 sibling had been
identified as a symptomatic SM case in the prevalence
study. The 8 litters comprised a total of 35 dogs
(Fig 1B). Seventeen dogs expressed clinical signs of
SM, whereas 17 dogs expressed no signs of SM. One
dog was excluded as it had been euthanized at the age
of 15 weeks because of severe seizures.
Twenty-two of 34 dogs (63%), including 11 dogs
identified as symptomatic SM cases in the prevalence
study, were allowed by the owners to participate in full
clinical work-up including MRI. Ten owners declined
to let their dogs participate in the MRI investigation,
primarily because of concerns associated with anesthe-
sia. One 5-year-old dog had been euthanized the year
before because of expression of severe signs consistent
with SM and could therefore not be investigated, and
the investigators excluded 1 dog because of severe
heart disease.
Thirteen of the 22 dogs (59%) were classified as
symptomatic SM cases, whereas 9 dogs displayed no
clinical signs of SM. MRI scans, however, revealed
syringes in the cervical spinal cord in 21 of 22 dogs
(95%); the remaining dog (expressing no clinical signs
of SM) had a presyrinx (Table 1). Thus, the MRI
investigation revealed that 8 dogs were clinically silent
(asymptomatic SM-positive cases), although having a
syrinx.
There was no statistical association between expres-
sion of clinical signs and the presence of syringes
(P = .41). A positive predictive value of the MRI scan
was calculated to 0.62 (the probability that a dog
would express clinical signs if it had a syrinx). Syrinx
diameter and syrinx : spinal cord ratio was evaluated
on T2W transverse sequences in 19 dogs. Two dogs
were excluded because the MRI studies were incom-
plete. The syrinx diameter varied from 0.3 to 0.8 cm.
The total mean of the maximum syrinx diameter was
0.55 cm. The mean maximum syrinx diameter was
0.63 cm in symptomatic dogs and 0.4 cm in asymp-
tomatic dogs. The data demonstrated that
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Fig 1. (A) Flow diagram, prevalence study—study phase I. aSix responders excluded because of euthanazia of the dogs before the age
of 6, 5 because of incomplete questionnaires. bSixty-one females and 62 males. cClinical signs reported by the owners, validated on sub-
sequent telephone interview. (B) Flow diagram, litter cohort study—study phase II. aIdentified in study phase I (of all eligible Danish
CKCS born in 2001). bExcluded because of euthanazia in 2001. cIncluding 11 dogs identified and validated in study phase I. dTen dogs
excluded because of reluctant owners, 1 because of euthanazia, 1 because of severe heart disease. (C) Flow diagram of the 2012 long-
term follow-up study—study phase III. aTwo owners declined to participate, 1 answer was excluded.
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symptomatic dogs had a significantly wider syrinx
diameter than asymptomatic dogs (P < .01). The total
mean syrinx : spinal cord ratio was 0.58. Symptomatic
dogs had a significantly greater mean syrinx : spinal
cord ratio (0.66), when compared to asymptomatic
dogs, which had a mean syrinx : spinal ratio of 0.43
(P < .01). The cranial limit of the syrinx was C2 in 17
of the 21 dogs (81%), C3 in 3 dogs (14%), and C1 in
1 dog (5%). Syrinx asymmetry (ie, unilateral dorsolat-
eral deviation of the cavity) was observed in 6 (5
symptomatic and 1 asymptomatic) dogs. Fisher’s exact
test of the association between symmetry versus asym-
metry and expression of clinical signs (yes/no) was
nonsignificant (P = .19). CM was identified in 22 of 22
dogs (100%). OME was present in 11 dogs (5 symp-
tomatic and 6 asymptomatic SM cases).
Estimation of Heritability. Heritability of symptom-
atic SM in dogs >6 years of age was calculated using
information on difference in mean liability within the
population and within related individuals to an
affected animal, respectively.36 Using the data pre-
sented (Table 2), the heritability was calculated at
0.81. In support of the high heritability, the difference
between prevalence of symptomatic SM in the popula-
tion and in the ones that were related to an affected
full sibling was statistically significant (chi-
square = 9.3; df = 1; P < .05).
Phase III—5-year Follow-up (2012)
Thirty-one of 34 dogs from the 2007 litter cohort
(16 symptomatic and 15 asymptomatic dogs) partici-
pated in follow-up in 2012, where the dogs were
11 years old (Fig 1C). Two owners declined and 1 dog
was excluded because of an incomplete interview.
Eleven of the 31 dogs (35%) were alive, while 20
(65%) had been euthanized. Euthanasia was directly
related to signs of SM in 4 dogs (20%). Thirteen of 16
symptomatic dogs remained symptomatic during the
study period (Table 3A). With respect to expression of
signs, 4 dogs experienced progression, 5 dogs remained
status quo, 4 dogs experienced regression (3 with treat-
ment) and 3 dogs became asymptomatic (1 with treat-
ment) during the study period. Fourteen of 15
asymptomatic dogs remained asymptomatic during the
study period, whereas 1 dog (with a MRI-confirmed
syrinx in 2007) developed clinical signs of SM from
2007 to 2012.
When evaluating the 22 dogs participating in the
clinical and MRI investigation in 2007 separately, the
following results were obtained (Table 3B): Twenty of
22 dog owners participated in the 2012 follow-up,
including 11 symptomatic SM cases and 9 asymptom-
atic SM cases (8 dogs with a MRI-confirmed syrinx
and 1 dog with a presyrinx). Ten of 11 symptomatic
SM cases remained symptomatic, whereas 1 previously
symptomatic SM case became asymptomatic during
the study period (without treatment). With respect to
the expression of clinical signs in the 10 dogs, which
remained symptomatic, 4 dogs deteriorated, 3 dogs
remained status quo, and 3 dogs improved (with treat-
ment) during the study period. Eight of 9 asymptom-
atic SM cases remained asymptomatic, whereas 1 dog
developed clinical signs of SM during the study period.
Discussion
This study estimated a prevalence of 15.4% of
symptomatic SM in Danish CKCS born in 2001
(>6 years old) and demonstrated that genetic factors
strongly influence the clinical expression of SM.36 The
study furthermore reported that only a minority of
asymptomatic dogs with a MRI-confirmed syrinx at
6 years develop clinical signs later in life.




SM Cases (n = 9)
In Symptomatic
SM Cases (n = 13) P-Value
Syrinx present/total (%) 21/22 (95) 8/9 (89) 13/13 (100)
Syrinx diameter T2W (cm), mean (range) 0.55 (0.3–0.8) 0.4 (0.3–0.8) 0.63 (0.3–0.8) .01
Spinal cord diameter (cm), mean (range) 0.94 (0.7–1.1) 0.9 (0.8–1.0) 0.96 (0.7–1.1) .08
Syrinx : spinal cord ratio, mean (range) 0.58 (0.3–0.86) 0.43 (0.3–0.8) 0.66 (0.33–0.86) .01
Asymmetric syrinx/total (%) 6/21 (29) 1/8 (13) 5/13 (38) .19
Cerebellar herniation/total (%) 21/21 (100) 8/8 (100) 13/13 (100)
MRI, magnetic resonance imaging; CKCS, Cavalier King Charles Spaniel; SM, syringomyelia; T2W, T2 weighted.
Table 2. Prevalence of symptomatic syringomyelia used for heritability estimation.
No. Non-affected Individuals No. Affected Individuals Frequency
In the population 104 19 0.1544
In full sib families 17 9a 0.3461
In remaining populationb 87 10 0.1031
aThe 9 individuals represent the 17 affected dogs minus the 8 index cases/propositus used for the selection of the families.
bUsed for calculation of chi-square.
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The dogs under investigation were older than
6 years of age, which served to secure that clinical
signs of SM would have evolved at the time of inclu-
sion. For a cross-sectional study based on mailed ques-
tionnaires, a response rate of 56% is considered to be
good.38 It is possible that the prevalence estimate is
biased by the fact that owners with experience of SM
might be more inclined to reply, whereas others may
neglect signs of SM. Had all 240 owners returned the
mailed questionnaire and had no new symptomatic
cases been identified; the minimum prevalence had
been 7.9% (19/240). The prevalence estimate was
based on owner-reported clinical signs of SM, a tele-
phone validation procedure, and a clinical evaluation,
which served to further confirm the presence of clinical
signs and rule out potential differential diagnosis. Five
of the 19 dogs, which contributed to the prevalence
estimate, did not participate in the clinical evaluation,
and although nothing in the dogs’ history indicated
other diagnosis than SM, this is a weakness to the
study, as we cannot exclude that some dogs were
included as false-positive cases. However, 11 of the 19
dogs (60%) which participated both in the prevalence
study and litter cohort study all had a MRI-confirmed
syrinx and this supports that the dogs which expressed
clinical signs of SM were true SM cases.
This study identified a substantial number of clini-
cally silent dogs although having a syrinx and having
symptomatic littermates. Symptomatic SM cases had a
significantly greater syrinx diameter and a larger syr-
inx : spinal cord ratio compared to the group of
asymptomatic SM cases which confirms previous
reports.25
Our data allowed us to estimate heritability of the
expression of symptomatic SM in CKCS 6 years of age,
which has not previously been done. The heritability of
SM diagnosed by a single MRI diagnosis without fol-
low-up on clinical status has been estimated at 0.37,1
whereas heritability of symptomatic SM was estimated
at 0.81 in this study. It is apparent that the development
of a syrinx does not always result in a clinical expres-
sion of signs of SM, and thus there may not be a dis-
crepancy between these results. Although the
heritability estimate for symptomatic SM might be an
overestimation because of the fact that there is a poten-
tial bias in the prevalence study (dog owners with
affected dogs might be more inclined to participate), the
heritability is clearly very high. Per definition heritabil-
ity is measured by estimating the relative contribution
of genetic and nongenetic differences to the total pheno-
typic variation in a population.36 The estimated herita-
bility of symptomatic SM indicates that genetics explain
most of the total phenotypic variance in the population.
As this study found an equal number of symptom-
atic and asymptomatic dogs with OME, and CM was
confirmed in all MRI scanned dogs, it was not possible
to examine if CM, OME alone, or both could have
contributed to some of the clinical signs reported by
the owners.
Finally, we acknowledge that the results of this
study are affected by the drawbacks inevitably associ-
ated with epidemiologic and clinical studies, where it is
seldom possible to motivate all owners to allow their
dogs to participate in all planned procedures. It lies
within the design of the study that all dogs should
undergo the same standardized investigations as
described in details in the materials and methods sec-
tion. Being an epidemiologic study where the investiga-
tors did contact the owners, we must however respect
that in some cases, owners do not want to participate
in full work-up. In that case, the investigators must
thoroughly determine for each dog if it can be defined
as a true case based on the collected information. We
also acknowledge that some of the choices made in
2007 regarding the study design may have influenced
the results, eg, that measuring syrinx size on T2W
images obtained from a low field system was subopti-
mal.39 MRI identification of a syrinx is presently the
gold standard for diagnosing SM. The results of this
study provides information which necessitate further
examination of factors contributing to disease expres-
sion and progression, and to the threshold of outbreak
of clinical signs.
Conclusions
This study of Danish CKCS estimated a high preva-
lence of symptomatic SM and found a high impact of




Status Quo Deterioration Improvement Unknown
A
Symptomatic SM cases 17 5 4 7a 1
Asymptomatic SM cases 17 14 1b 2
B
Symptomatic SM cases 12 3 4 4c 1
Asymptomatic SM cases 10 8 1b 1
aThree dogs changed status from symptomatic to asymptomatic.
bOne dog changed status from asymptomatic to symptomatic.
cOne dog changed status from symptomatic to asymptomatic.
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   genetics on the clinical expression of the disease. Dogs
with a MRI-confirmed syrinx and clinical signs are at
risk of euthanasia, whereas dogs with a MRI-con-
firmed syrinx which are asymptomatic by the age of 6,
seem to have a good chance of never developing such
signs. It is of interest to conduct further studies investi-
gating factors, which may influence the threshold of
outbreak of clinical signs of SM.
Footnotes
a See: http://www.neologica.it/html/RemotEye.php
b Microsoft Excel 2008 for Mac Version 12.3.6
c Takeda Pharma A/S, Langebjerg 1, DK-4000 Roskilde, Den-
mark
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A B S T R A C T
It is assumed that Cavalier King Charles spaniels with Chiari-like malformation and syringomyelia
experience central neuropathic pain. An association between spinal cord parenchymal lesions and
specific clinical signs (e.g. spontaneous and evoked scratching, withdrawal, and paroxysmal pain
manifestations with vocalisation) has been suggested. This led to the hypothesis that mechanical sensory
threshold is altered in clinical cases. The aim of this study was to quantify the cervical mechanical sensory
threshold using Semmes-Weinstein monofilaments in nine Cavalier King Charles spaniels with Chiari-
like malformation and assumed syringomyelia-associated central neuropathic pain compared to eight
control dogs. Clinical and neurological examination including magnetic resonance imaging was
undertaken.
Mean mechanical sensory threshold was not significantly different between case and control
dogs (t-test on log10 transformed data; P = 0.25). Substantial variation within and between dogs was
seen, with individual thresholds ranging from 0.04 to 26 g in case dogs and from 0.02 to 10 g in control
dogs. Based on these results, it is unlikely that Cavalier King Charles spaniels with Chiari-like
malformation and syringomyelia have increased mechanical sensation characterised by lower
mechanical sensory threshold when quantified with Semmes-Weinstein monofilaments. Whether
clinical cases experience central neuropathic pain remains unknown. The assessment of sensory
function in dogs with assumed central neuropathic pain should be multimodal and include not only
mechanical but also tactile and thermal threshold quantification. The use of threshold quantification in a
clinical setting is challenging due to an insufficient signal relative to the biological background noise
within and between dogs.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
It is assumed that Cavalier King Charles spaniels (CKCS) with
Chiari-like malformation (CM) and syringomyelia (SM) experience
central neuropathic pain (Rusbridge, 1997; Rusbridge et al., 2007;
Rusbridge and Jeffery, 2008; Plessas et al., 2012; Rutherford et al.,
2012). Affected dogs express various clinical signs including
spontaneous and evoked scratching, reaction to touch on the
head and neck region and, in severe cases, paroxysmal pain
manifestations with vocalisation (Sanchis-Mora et al., 2016; Sparks
et al., 2018). This aberrant behaviour is suggested to result from
sensory threshold alterations, resulting in dysaesthesia and
allodynia, and it has been argued that there is an association
between the structural lesions of the spinal cord parenchyma and
sensory threshold alterations (Rusbridge et al., 2007; Rusbridge
and Jeffery, 2008; Hatem et al., 2010; Hu et al., 2012; Plessas et al.,
2012; Schmidt et al., 2013).
In humans, SM associated with CM has been described to
cause central neuropathic pain as a consequence of the
somatosensory nervous system lesions and abnormal spinotha-
lamic function (d’Angers and Prosper, 1827; Spiller, 1923; Levy
et al., 1983; Hatem et al., 2010; Jensen and Finnerup, 2014). The
pathophysiological mechanisms underlying neuropathic pain are
associated with spinal and supraspinal nociceptive hyperexcit-
ability and central sensitisation (Latremoliere and Woolf, 2009;
Cohen and Mao, 2014; Jensen and Finnerup, 2014). Somatosen-
sory disturbances include dermatomal patterns of mixed loss of
thermal sensitivity, paradoxical hypersensitivity and tactile
* Corresponding author.
E-mail address: mast@sund.ku.dk (M.S. Thoefner).
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allodynia (Gamache and Ducker, 1990; Hida et al., 1995; Ducreux
et al., 2006; Hatem et al., 2010).
In humans, quantitative sensory testing is used in combination
with clinical examination and questionnaires to assess the
neuropathic pain phenotype by application of thermal, mechanical
and tactile stimuli (Cruccu et al., 2010; Haanpaa et al., 2011; von
Hehn et al., 2012). This validated psychophysiological measure of
perception assesses the function of peripheral myelinated and
unmyelinated sensory fibres and nociceptive pathways of the
central nervous system. The subject’s sensory threshold for heat
and cold is assessed by using a thermal probe; the threshold for
tactile stimuli is assessed using monofilaments; for pinprick
sensation weighted needles are used and sensitivity to vibration is
assessed by the application of a tuning fork or a vibrameter
(Greenspan, 2001; Cruccu et al., 2010; Thaisetthawatkul, 2014).
In dogs, a number of studies have investigated the use of
monofilaments and handheld electronic devices for mechanical
sensory threshold (MST) quantification. The response has been
evaluated in healthy dogs and in dogs with acute, nociceptive pain
and to assess the analgesic effect of systemic ketamine, opioids and
local analgesics (Duque et al., 2004; KuKanich et al., 2005a,b;
Fitzpatrick et al., 2010; Case et al., 2011; Hardie et al., 2011;
Kukanich and Papich, 2011; Pieper et al., 2011; Brydges et al., 2012;
Moore et al., 2013; Sanchis-Mora et al., 2017). However, the use of
MST quantification to evaluate somatosensory function and the
relationship between sensory threshold and behavioural indica-
tors of pain in dogs with anticipated central neuropathic pain has
not previously been reported. The primary aim of this study was
therefore to quantify the cervical MST with Semmes-Weinstein
monofilaments in CKCS with assumed mechanical threshold
alterations and central neuropathic pain associated with SM. We
hypothesise that the structural spinal cord parenchymal lesions
result in a significant difference in MST between CKCS with
syringomyelia-associated scratching and MRI-confirmed SM-
negative control dogs without clinical signs.
Materials and methods
A prospective case-control study was conducted at the University Hospital for
Companion Animals’ Referral Neurology Clinic, Department of Veterinary Clinical
Sciences, University of Copenhagen. Client-owned, pedigreed CKCS were enrolled in
the study between 19 December 2013 and 21 September 2015. The study was
approved by the Danish Animals Experiments Inspectorate (Approval date 12
January 2015; Approval number 2015-15-0201-00456) and the local Ethics and
Administration Committee (Approval date 28 January 2014; Approval number
2014-5).
Initially, the standardised questionnaire published by Rutherford et al. (2012)
was used to screen all dogs before enrollment in the study and to establish the
individual dog’s neuropathic pain score. Owners were interviewed by the principal
investigator about their dog’s general health status, medical history, clinical signs,
behaviour, and quality of life. Enrollment criteria for case dogs included uni- or
bilateral spontaneous scratching directed at the neck or shoulder. Enrollment
criteria for control dogs included age >5 years. The rationale behind the
conservative age-limit was to ensure that control dogs were truly SM-negative.
To ensure the inclusion of control dogs without altered nociception or chronic pain,
potential control dogs were excluded if they had a previous or present history of
neurological or musculoskeletal conditions, skin- or ear conditions causing
pruritus, had undergone surgery or received anti-epileptic medications. Gestating
or lactating bitches and potential control dogs treated with analgesics or anti-
inflammatory agents <6 weeks prior to enrollment were excluded.
All dogs were assessed by the principal investigator and underwent a clinical
and neurological examination including otoscopy and ear swab cytology, urinalysis,
haematological, biochemical and thyroid profile assessment. Dogs were excluded if
the clinical evaluation revealed dermatologic conditions causing pruritus,
neurological or musculoskeletal conditions causing pain or conditions contra-
indicating anaesthesia.
Mechanical sensory threshold quantification
The MST was quantified with Semmes-Weinstein monofilaments by the
principal investigator after clinical and neurological examination and before MRI. To
prevent discrepancies between owner-reported clinical signs, and clinical,
neurological, and MRI findings and MST test results due to potential disease
progression, the time between the interview with the owner and the clinical
examination including MST quantification and MRI was <14 days.
To reduce the variation between dogs, the principal investigator examined all
dogs under the same conditions in the same standard examination room where
there was background noise related to a normal teaching and referral hospital
environment. The dog was placed standing on an examination table. MST
quantification was video recorded using a smartphone (iPhone 6s, Apple). One
of three research assistants performed the video recordings sitting on a rolling stool
in front of the table to follow the dog’s movements without losing focus on the dog’s
face. Owners were placed behind the camera operator to maintain the dog’s
attention towards the camera. No sensory inputs beside the applied filament were
allowed, and after each time the dog’s position was corrected, there was a 10 s pause
before resuming the threshold quantification.
Three testing points were defined at the lateral aspects of the neck innervated
by the spinal cord segments C1–C6 (Fig.1). The initial stimulus side (left or right side
of the neck) was chosen at random by throwing a dice (simple randomisation).
Twenty Semmes-Weinstein monofilaments (Touch Test 20 Piece Full Kit, North
Coast Medical) ranging from 0.008 to 300 g could be applied in ascending order,
until one of five predefined behavioural responses was elicited (attentional shift
towards the stimulus, body twitch, headshake, evoked scratching and avoidance/
withdrawal response; Table 1).
Stimulation was initiated at testing point I cranial to the spina scapula (Fig. 1).
The filament tip was placed in contact with the skin and a light pressure was applied
until the filament flexed. Each stimulus lasted 3 s followed by a 10 s interval. If no
response was elicited by the applied monofilament at testing point I, the same
monofilament was applied to testing point II and – if no response – to testing point
III. If no response was elicited with the finest monofilament (i.e. 0.008 g) at any of
the testing points I–III, the procedure was repeated with the next finest
monofilament (i.e. 0.02 g). Increasing monofilament diameters were used until
one of the five predefined behavioural responses was elicited. After a 10 s pause, the
procedure was then repeated with the same monofilament to ensure that the
response was reproducible (i.e. that two consecutive stimuli of the same intensity
would elicit the same response). After threshold quantification on the initial
stimulus side, the test procedure was repeated at the contralateral side of the neck.
The video recorded MST quantification was assigned a random number using
random permutation before it was saved in a database. To ensure masked
evaluation, the videos were evaluated without sound by the principal investigator 4
Fig. 1. Anatomical localisation of the testing points on the lateral aspects of the
neck. To expose the testing points, the dog’s pinnae were wound with VetFlex
(Kruuse). The region of interest was visually outlined between two parallel lines –
one defined by the spina scapula and the other parallel to the first line intercepting
the wing of the atlas. The region of interest was then visually divided into three
zones, with testing points I–III in the centre of these three zones (demarked I, II and
III within the circles). Stimulations with Semmes-Weinstein monofilaments (range
0.008–300 g) were used to quantify the mechanical sensory threshold on both sides
of the dog’s neck and is reported as a mean of the two measures.
M.S. Thoefner et al. / The Veterinary Journal 246 (2019) 92–97 93
  65
   
months after study termination. The primary outcome ‘mechanical sensory
threshold’ was defined by the monofilament size in g that elicited a behavioural,
reproducible response (Table 1). The sensory threshold was quantified on both sides
of the neck and was reported as the mean of the two measures.
MRI protocol
Dogs were anaesthetised and placed in sternal recumbency. Case dogs
underwent MRI (0.2 Tesla Vet-scan, Esaote) of the neurocranium and the spinal
cord (C1–C6). The control dogs underwent MRI of the neurocranium from the
interthalamic adhesion and as far caudal as possible but at least to the C4/C5
intervertebral disc space. Both protocols included T1-weighted (T1W) transverse,
sagittal and dorsal sequences and T2-weighted (T2W) transverse and sagittal
sequences. For specific details on the MRI protocol, we refer to the supplementary
information (See Appendix: Supplementary MRI protocol). Scans were transferred
to the web-based DICOM (RemoteEye, NeoLogica) and evaluated by an assessor
masked to group allocation (UW). Syrinx evaluation and measurements were
performed using transverse T1W MR images. SM was defined as a fluid-filled cavity
in the cervical spinal cord parenchyma with a diameter  2 mm. CM was defined as
cerebellar indentation with or without cerebellar herniation into or through the
foramen magnum. The presence of T2 hyperintensity within the tympanic bulla led
to the tentative diagnosis ‘otitis media with effusion’ (OME). The term OME will be
used in this paper for simplicity although the authors acknowledge that the term is
very specific and suggests a cellular diagnosis.
Statistical analysis
In a pilot study, dogs that had previously undergone clinical work-up for clinical
signs associated with SM or pre-breeding MRI screening were invited to participate
in MST quantification after clinical evaluation. In this pilot study, MST was
quantified in 26 MRI-confirmed cases with SM-associated scratching and nine MRI-
confirmed, SM-negative control dogs without clinical signs. Based on a normal
distribution approximation and the assumption that the difference in mean MST
between case and control dogs was 30% (standard deviation [SD]  20) with α = 0.05
and β = 0.8, a minimum sample size of n = 9 in each group was calculated. To identify
nine true negative control dogs, it was estimated that the required sample size was
20 CKCS without clinical signs associated with SM, since approximately 50% of all
CKCS older than 5 years of age without clinical signs associated with SM are SM-
positive (Parker et al., 2011).
To ensure that all data met the assumptions of parametric tests, MST data were
log10 transformed before data analysis. In case of an outcome of ‘no response to
maximum stimulation with 300 g,’ the numeric value of the MST was right censored
and assigned ‘350’ in the data set. Data was analysed using SAS Studio 3.71 (SAS
Institute), with statistical significance set at P < 0.05. To test the hypothesis of no
difference in mean MST between case and control dogs, an unpaired, two-sided t-
test was applied. For dichotomous outcomes, Fisher’s exact test was applied.
Results
Nine CKCS older than 1 year of age with clinical signs associated
with MRI-confirmed SM were included as cases. Of 20 potential
control dogs without clinical signs associated with SM that
underwent clinical work-up, eight CKCS (40%) > 5 years of age were
included as MRI-confirmed negative control dogs. Twelve dogs
without clinical signs were excluded after MRI, because they were
SM positive. The descriptive characteristics of case and control
dogs are presented in Table 2. There was no significant difference in
sex distribution (P = 0.62) and mean bodyweight (P = 0.47) between
case and control dogs. The median age of case and control dogs was
3.34 years (interquartile range, IQR 0.92) and 7.23 years (IQR 1.83),
respectively. The significant difference in age between the two
groups (P < 0.0001) reflected the intentional age-specific selection.
The primary descriptive results of the owner interview are
presented in Supplementary Table 1. Clinical evaluation revealed
no dermatologic conditions causing pruritus, neurological or
musculoskeletal conditions causing pain or conditions contra-
indicating anaesthesia. Haematological, biochemical and thyroid
profiles, urinalysis and ear swabs were unremarkable. None of the
dogs had received analgesics within the previous 7 days before
clinical evaluation and threshold quantification. The mean
neuropathic pain score was 1.59 (range 1.0–2.29) in case dogs
and 0.0 in all control dogs.
CM was present in all case and control dogs. The cases had a mean
syrinx:spinal cord ratio of 0.53  0.14 (range 0.29–0.71). The cranial
limit of the syrinx was localised within the C3 segment in four of nine
case dogs (44%). Six case dogs presented with asymmetric syrinxes.
Spontaneous scratching was unilateral and directed to the same side
as the asymmetric syrinx in four of the six case dogs (67%). In the
three case dogs with symmetric syrinxes, the spontaneous scratch-
ing was unilateral (see Appendix: Supplementary Table 1). OME was
found in three of nine case dogs (56%) and in five of eight control dogs
(63%). The occurrence of OME (unilateral, bilateral or none) was not
significantly different between the two groups (P = 0.35).
Mechanical sensory threshold quantification
The median MST was 0.9 g (IQR 175.1) in case dogs and 0.24 g
(IQR 5.1) in control dogs (Table 3a). Mean MST was not significantly
different between case and control dogs when comparing log10
transformed data (P = 0.25). In case dogs, a reproducible behav-
ioural response (Table 1) was elicited by filaments sized between
0.04 and 26 g. In control dogs, filaments sized between 0.02 and
10 g elicited a reproducible behavioural response.
No significant differences were found between case and control
dogs when the results of initial mean threshold quantification
(P = 0.09) and contralateral mean threshold quantification (P = 0.99;
Table 3a) were compared. Mean threshold did not differ between
case dogs with symmetric and asymmetric syrinxes (P = 0.54;
Table 3b). When comparing initial vs. contralateral mean thresh-
olds, no differences were found within the control group (P = 0.75)
or within the case group (P = 0.06; Table 3c and d). A comparison of
mean thresholds for affected and non-affected sides in case dogs
with unilateral scratching also revealed no difference (P = 0.37).
Table 1
An ethogram was designed for objective and standardised evaluation of possible behavioural responses elicited by stimulations with Semmes-Weinstein monofilaments in
Cavalier King Charles spaniels with clinical signs of MRI-confirmed syringomyelia and in control dogs. If one of the five responses were elicited and reproduced, the filament
size (g) was recorded.
Behaviour Description of the dog’s response when stimulated with the Semmes-Weinstein monofilament
Attentional shift The head is turned towards the stimulus (>90 lateroflexion of the neck relative to straight forward)
Body twitch The cranial part of the body is moved in a twitch
Headshake Spontaneous headshake
Evoked scratch The stimulus elicits a scratch episode
Avoidance/withdrawal response A deliberate movement away from the stimulus
Table 2
Demographics of the 17 Cavalier King Charles spaniels included as case and control
dogs, with continuous variables reported as median (range [interquartile range]),
and categorical variables reported as n (%).
Cases (n = 9) Controls (n = 8)
Age (years) 3.34 (1.67–5.74 [0.92]) 7.23 (5.62–9.13 [1.83])
Sex
Female 6 (67%) 5 (63%)
Female spayed 1 (11%) 0 (0%)
Male 2 (22%) 3 (37%)
Male castrated 0 (0%) 0 (0%)
Bodyweight (kg) 9.4 (7.1–10.9 [1.8]) 8.5 (5.8–10.2 [3.13])
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Threshold responses were most frequently elicited at testing
point I in case dogs and at testing point II in control dogs (in 50%
and 63%, respectively, of all stimulations that led to a behavioural
response). The MST quantification test procedure was well
tolerated and completed in all dogs. The mean duration of the
procedure (8 min 40 s in case dogs and 4 min 39 s in control dogs)
was not significantly different between the groups (P = 0.054).
Discussion
This study investigated the hypothesis that spinal cord
parenchymal lesions in CKCS with syringomyelia-associated
clinical signs and MRI-confirmed SM would result in MST
measurements that were significantly different from those in
control dogs. Since tactile allodynia is one of the most commonly
observed evoked pains in human patients with SM (Hatem et al.,
2010), we expected to demonstrate lower thresholds as an
indication of increased sensation in the case dogs. Despite a very
strict and detailed study protocol and a very consistent testing
procedure, we were unable to demonstrate the expected difference
between case and control dogs. Subgroup analysis within the
control dogs showed no differences in MST between the side of the
neck used for initial stimulation and the contralateral side. This
finding is consistent with previous findings in MST quantification
studies in healthy dogs (Sanchis-Mora et al., 2017) and healthy
humans (Rolke et al., 2006). Within the case dog group, the overall
comparison of thresholds between the two sides of the neck
revealed no differences. Additionally, we expected lower thresh-
olds in case dogs with asymmetric syrinxes compared to those
with symmetric syrinx distribution. We also expected that the
thresholds in case dogs with unilateral scratching would be lower
on the affected vs. the contralateral side, as previously reported in
dogs with chronic pain (Brydges et al., 2012). However, subgroup
analysis revealed no difference in MST related to either syrinx
distribution or lateralisation of clinical signs.
Based on the results from our pilot study, we expected to detect
a difference in MST between case and control dogs. Localisation
and syrinx distribution, OME status and severity of clinical signs
and neuropathic pain score are among the factors that varied
between case dogs in the pilot study and those enrolled in the
prospective study. The analgesic treatment had been discontinued
by the owners in some of the pilot case dogs prior to MST
quantification, and for most dogs this led to increased intensity of
clinical signs and an assumed change in sensory threshold. These
factors may have influenced the results of the pilot study which led
to an inadequate sample size to detect a difference between groups
in the present study.
In agreement with previous findings (Thofner et al., 2015), the
prevalence of CM and OME was not different between dogs with
and without clinical signs. Nevertheless, the authors speculate that
CM and varying degrees of OME and coexisting deficiencies in
eustachian tube pressure-equalisation could cause scratching
directed at the ear, head and neck in some cases. Similarly, a
recent study of owner-reported clinical signs in CKCS with CM–SM
(Sparks et al., 2018) has suggested a possible lack of association
between SM and the clinical pain phenotype, since CKCS with CM
without SM can present with clinical signs previously reported to
be associated with CM–SM (Rusbridge et al., 2007; Schmidt et al.,
2013). The ideal control group would be CKCS without CM, SM and
OME. The ideal case definition would accordingly have been a SM-
positive CKCS with SM-associated clinical signs without CM and
without OME. Unfortunately, the relative high frequency of both
CM, SM and uni- or bilateral OME in CKCS expressing SM-
associated clinical signs and clinically silent CKCS makes this
almost impossible (Cerda-Gonzalez et al., 2009; Parker et al., 2011;
Plessas et al., 2012; Sanchis-Mora et al., 2016).
In the search for a feasible and reliable diagnostic tool to
identify dogs with altered MST and to evaluate treatment efficacy,
our study was designed to mimic a clinically realistic situation. This
may have increased the background noise relative to the signal. The
methodological variation due to fluctuations in room temperature
and individual (lack of) tolerance to distractions in and outside the
room could have been reduced by using a quiet room at a constant
temperature and by asking the owners to wait outside during
threshold quantification. Variation in hair coat, thickness of the
skin, dermal blood-flow and the distribution of cutaneous
nociceptors are factors that have been reported to affect the
sensory threshold quantification outcome in other species (Love
et al., 2011). Hair coat variation has been accounted for in previous
studies by hair clipping (Knazovicky et al., 2016; Sanchis-Mora
et al., 2017). We decided to omit this due to the risk of skin trauma
and local inflammation on the relatively large area of interest and
the reluctance of owners, especially those who owned breeding
and show dogs without clinical signs.
We chose three testing points on each side of the neck and
decided that a reproducible response at any one site was enough to
determine the MST of the given side of the neck. We also decided
that the individual dog’s MST should be reported as the mean of
MSTs quantified on each side of the neck. The anatomical variation
in lesion localisation among SM-positive CKCS (Loderstedt et al.,
2011) was not accounted for in the protocol. Furthermore, the
order in which the testing points were stimulated could have been
randomised. It is debatable whether a mean of the MSTs quantified
on each side of the neck is a representative measure of MST in
Table 3
The mean of each dog’s paired measurements on both sides of the neck represents the primary outcome mechanical sensory threshold (MST; g) and is reported here as median
(range [interquartile range]) MST, in case and control dogs (a); within case dogs with symmetric and asymmetric syrinxes, respectively (b); and with the sub-group analysis
comparing initial versus contralateral MST within control dogs (c) and case dogs (d).
(a) Cases Controls P
Median MST 0.9 (0.06–175.7 [175.1]) 0.24 (0.02–175.2 [5.1]) 0.25
Initial MST 0.6 (0.04–350 [349.8]) 0.16 (0.02–10 [0.3]) 0.09
Contralateral MST 0.4 (0.04–15 [1.3]) 0.07 (0.02–350 [5.3]) 0.99
(b) Cases, symmetric syrinx Cases, asymmetric syrinx P
Median MST 20.5 (0.1–175.2 [175.1]) 0.6 (0.06–175.7 [175.1]) 0.54
(c) Controls, initial MST Controls, contralateral MST P
Median MST 0.16 (0.02–10 [0.3]) 0.07 (0.02–350 [5.3]) 0.75
(d) Cases, initial MST Cases, contralateral MST P
Median MST 0.6 (0.04–350 [349.8]) 0.4 (0.04–15 [1.3]) 0.06
Symmetric syrinx 26 (0.04–350 [350]) 0.4 (0.2–15 [18.8]) 0.55
Asymmetric syrinx 0.5 (0.07–350 [349.8]) 0.2 (0.04–1.4 [1.4]) 0.18
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individual dogs. In dogs that did not respond to maximum
stimulation with 300 g, an arbitrary numeric value of 350 g was
assigned (right censoring), which resulted in an arbitrary mean
MST. Based on our experience, a better solution would have been to
stimulate only one testing point on each side of the neck, or
alternatively, to test the affected side in dogs with unilateral
clinical signs. This approach would have increased the robustness
of the dataset.
In human patients with neuropathic pain, a non-affected body
area is chosen as a reference area to compare the quantitative
sensory test results of the affected body area. This can be done
because the patient is asked whether a specific body region is
painful or not. The definition of a reference area in dogs is
complicated due to the variability of the anatomical localisation of
lesions in SM-positive dogs with clinical signs, and the veter-
inarian’s lack of verbal communication with the dog. Moreover, a
previous study (Williams et al., 2016) reported that C2 and C4
anatomical localisations produced different MST thresholds in SM-
positive CKCS with and without clinical signs.
A major challenge was the evaluation of the dogs’ responses to
stimuli. The sensory threshold is a quantifiable measure, but the
endpoint is determined subjectively, which can vary between
observers and hence create bias. In a clinical setting, the risk of
missing or misinterpreting a response is important. In the present
study, the dogs’ behavioural responses to stimuli were video-
recorded and re-evaluated by the principal investigator masked
to the group allocation of the dog in order to reduce inter-
investigator bias.
MST quantification is one of several modalities used to assess and
quantify sensory deficits. Studies of the complete somatosensory
profile as described by Sanchis-Mora et al. (2017) should be
undertaken to assess whether CKCS with clinical signs associated
with CM–SM have altered sensory thresholds, which could indicate
central, neuropathic pain. A thorough clinical characterisation of a
larger cohort of case and control dogs would enable multivariate
analysis and classification of dogs into distinct sensory subgroups.
Since the completion of the present study, several other groups have
published protocol validation and application studies (Harris et al.,
2015; Freire et al., 2016; Gorney et al., 2016; Knazovicky et al., 2017;
Sanchis-Mora et al., 2017). It is anticipated that these continuous
research efforts will lead to optimisation of the testing protocol and
hopefully enable methodological standardisation. Moreover, this
should lead to further insights regarding how and where to quantify
sensory thresholds, how to define a relevant reference area, how to
interpret the responses to stimuli, and how to analyse and report the
results.
Conclusions
The present study was unable to demonstrate a significant
difference in MST between CKCS with SM and control dogs in spite
of a very detailed and consistent testing procedure. The use of
threshold quantification in a clinical setting is challenging due to
an insufficient signal relative to the biological background noise
within and between dogs. A thorough clinical characterisation and
multimodal assessment of the somatosensory profile in a larger
group of case and control dogs, and including not only mechanical
but also tactile and thermal threshold quantification, would enable
multivariate analysis to assess the effect of CM, OME, lesion-
localisation and lateralisation of clinical signs on the somatosen-
sory profile. It is still unknown whether CKCS with CM–SM
experience central, neuropathic pain, but according to the findings
in our cohort of dogs with MST quantified with Semmens-
Weinstein monofilaments by our specific protocol, it is considered
unlikely that CKCS with clinical signs associated with MRI-
confirmed CM–SM have increased mechanical sensation.
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   Appendix A 
 
Supplementary MRI protocol 
Both protocols included T1- weighted (T1W) transverse images (T1-spin echo [SE] with a 
field of view [FOV] of 17 cm, time to echo [TE] of 18 milliseconds, time to repeat [TR] of 780-
1000 milliseconds, slice thickness 4.5 - 5 mm, a slice gap of 0,5 mm, and a number of excitations 
[NEX] of 3-4), T1W sagittal SE sequences (FOV: 17 cm, TE: 18 milliseconds, TR: 490 - 560 
milliseconds, slice thickness 4.5 mm, slice gap: 0,5 mm and NEX: 3-4), T1W dorsal SE sequences 
(FOV: 17 cm, TE: 18 milliseconds, TR: 490 milliseconds, slice thickness 4 - 4.5 mm, slice gap: 0,5 
mm and NEX: 3-4), T2-weighted (T2W) transverse sequences (high resolution turbo spin echo 
[TSE], FOV 17 cm, TE: 80 milliseconds, TR: 3.090 - 3970 milliseconds, slice thickness 4.5 - 5 mm, 
a slice gap of 0,5 mm and NEX: 1) and T2W sagittal TSE sequences (FOV 17 cm, TE: 80 
milliseconds, TR: 3.000 milliseconds, slice thickness 4.5 mm, a slice gap of 0,5 mm and NEX: 1). 
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Objective   Cavalier King Charles Spaniels with syringomyelia express clinical signs of central 
neuropathic pain. Predominant clinical signs of pain are scratching and paroxysmal pain 
manifestations with vocalisation. No evidence-based treatment for canine central neuropathic pain 
exists. Since pregabalin alleviates human neuropathic pain we aimed to investigate pregabalin’s 
effect on canine syringomyelia-related central neuropathic pain.  
 
Study design   An authority-approved, randomised, crossover superiority trial.  
 
Animals   Twelve client-owned dogs with magnetic resonance imaging-confirmed syringomyelia and 
clinical signs of central neuropathic pain, aged between 1.1 and 7.4 years, weighing between 8.2 
and 10.8 kg.  
 
Methods   Randomisation of dogs to either pregabalin 150 mg or placebo for 25 days and 48-h 
washout before crossover to the alternate phase of 25 days duration. The primary outcome was 
defined as number of scratching events during ten minutes of physical activity. The treatment effect 
was estimated using a generalised estimation equations model. Benefit-risk assessment of 
treatment was obtained through observation of side effects, adverse events and owner satisfaction.  
 
Results   The treatment effect estimate was an 84 % (CI95 = 75%, 89%) reduction in mean number 
of scratching events relative to baseline when compared to placebo (P = <0.0001). The administered 
dose range (13 - 19 mg/kg q 12 h) was well tolerated in all but one dog (withdrawn seven days after 
crossover to pregabalin due to ataxia). The most prevalent side effects were increased appetite in 
9/12 dogs and ataxia in 9/12 dogs. Improved quality of life was reported in all dogs. No adverse 
events were seen. No dogs needed rescue analgesia during the trial.  
 
Conclusion and clinical relevance   Pregabalin is superior to placebo in the reduction of clinical signs 
of syringomyelia-related central neuropathic in dogs. A dose range of 13 - 19 mg/kg q 12 h is safe to 





Cavalier King Charles Spaniels (CKCS) with Chiari-like malformation and syringomyelia (SM) express 
clinical signs of central neuropathic pain (CNeP) (Rusbridge et al. 2007; Rutherford et al. 2012; 
Hechler & Moore 2018). The clinical presentation of the canine SM phenotype is very diverse. 
Typical manifestations of discomfort and pain reported by the owners are spontaneous and evoked 
scratching, phantom scratching, paroxysmal pain manifestations with vocalisation and different 
aberrant behaviours e.g. nightwandering, hiding, avoidance of touch and grooming and reluctance 
to wear a collar or harness (Rusbridge et al. 2000; Sanchis-Mora et al. 2016; Sparks et al. 2018).  
To date no evidence-based recommendations for the treatment of clinical signs of SM-related 
CNeP has been published. The structural gamma-aminobutyric acid (GABA) analogue pregabalin 
(PGN) has been found effective for human neuropathic pain patients in several randomised 
controlled trials and is classified as a first-line analgesic (Siddall et al. 2006; Vranken et al. 2008; 
Cardenas et al. 2013; Finnerup et al. 2015). Accordingly, the primary aim of the study was to assess 
the efficacy and benefit-risk profile of PGN in dogs with clinical signs of CNeP associated with SM. 
We hypothesise that the analgesic efficacy of PGN is superior to placebo to reduce clinical signs of 
SM-related CNeP. 
 
Materials and methods 
The trial was conducted at the University Hospital for Companion Animals (UHCA). The study was 
approved by the Danish Medicines Agency (11th of April 2017, file number 2017020400) and the 
local Ethics and Administration Committee (20th of February 2017, file no. 2017-4). Informed 
content was obtained from all owners. 
 
Study population 
Eligible client-owned, purebred CKCS older than one year of age dogs should weigh ≥ 8 and ≤ 12 kg, 
express clinical signs of SM-related CNeP with MRI confirmed SM. Clinical signs of SM-related CNeP 
was defined as uni- or bilateral spontaneous scratching directed at the shoulder area. SM was 
defined as a fluid filled cavity in the spinal cord parenchyma with a diameter ≥ 2 mm on T1-weighted 




imidacloprid/permethrin or fluralaner) before inclusion. Pregnant or lactating dogs and dogs treated 
with any kind of analgesics 48 hours prior to inclusion were not eligible.  
Pre-inclusion visits were undertaken by the principal investigator (PI [MAST]) and a dedicated 
research veterinary technician. The questionnaire published by Rutherford et al. (Rutherford et al. 
2012) including questions regarding the dog’s general health status, medical history, clinical signs, 
behaviour and quality of life (QOL) was used to confirm eligibility and to establish the individual 
dog’s baseline neuropathic pain score. The dogs were walked on a predefined route for ten minutes 
to confirm that they expressed clinical signs of SM-related CNeP. The walk was video-documented 
to enable retrospective re-assessment of the dogs’ scratching profiles and quantification of 
scratching events. The dogs underwent a clinical and neurological examination, otoscopy, ear swab 
cytology, urine- and blood analysis including CBC, biochemical and thyroid profile before magnetic 
resonance imaging (MRI) of the neurocranium and cervical spinal cord parenchyma as previously 
described by Thoefner et al. (Thoefner et al. 2019) to rule out other causes of scratching than SM. 
 
Study design and blinding procedure 
This superiority trial was designed as a two-treatment two-period crossover trial with random 
assignment of elective dogs to treatment arm A with treatment sequence ‘PGN - placebo’ or 
treatment arm B with treatment sequence ‘placebo - PGN’ (Figure 1). The allocation ratio was 1:1. 
A simple randomisation code was used. To enrol a dog, the PI asked the owner to draw a random 
number from a non-transparent envelope. The random number corresponded to a unique trial code 
on the randomisation list generated by an online randomisation tool (www.randomization.com). 
The list was provided in a sealed envelope by the pharmacist who manufactured, packed and 
labelled the investigational agent and placebo capsules.  
Gelatine capsules of identical appearance containing either placebo or PGN (Lyrica; Pfizer, NY, 
USA) were provided in containers of identical appearance. Containers could only be distinguished 
by the label, which stated the unique trial code and ‘treatment period one’ or ‘treatment period 
two’. Thus, randomisation to treatment arm A or B was blinded to the PI and the owner. To eliminate 
any biased expectation of effect, the owners were not informed of the name of the investigational 
agent. The trial was continuously followed by an external monitor. The PI, owners, monitor and 




the end-of-trial. The dataset was completed and locked, and the code was not broken until data 
analysis were finalised.  
 
Intervention 
Patients randomised to treatment arm A received PGN PO, initially 150 mg q 24 hours for two days 
increasing to a targeted maintenance dose of 150 mg q 12 hours for 21 days, followed by a tapering 
phase of 150 mg q 24 hours for two days. The washout period (48 hours) was followed by crossover 
to the placebo-treatment period: one capsule q 24 hours for two days, one capsule q 12 h for 21 
days followed by 1 capsule q 24 h. The dogs randomised to treatment arm B were subjected to 25 
days of placebo-treatment, two days washout followed by 25 days of PGN-administration as 
described for dogs in treatment arm A (Figure 1). No concomitant analgesic treatment was allowed 
during the trial. If the owner or PI assessed a failure to respond that affected the dog’s QOL, the dog 
was withdrawn from the study and rescue analgesia was initiated.  
 
Outcome measures  
The outcomes were assessed five times in total: at the pre-inclusion visit where baseline data were 
collected, and at four follow-up visits (two visits in each treatment period, day 7, 21, 34 and 48 ± 2 
days).  
The primary outcome ‘number of scratching events during ten minutes of continuous, physical 
activity’ was documented in standardised, video-series of ten minutes duration and quantified by 
counting scratching episodes.  
Secondary outcome measures for scratching were assessed by the owner by means of the 11-
point numerical rating scale, SCR/NRS where 0=no scratching and 10=worst scratching imaginable. 
Subsequently, the owner was presented to a modified Faces Pain Scale designed for pain 
assessment in children with five faces, a colour-intensity scale beneath the faces and a horizontal 
sliding indicator (Hicks et al. 2001). The owners were asked to place the sliding indicator on the 
colour or face that corresponded to their assessment of their dogs’ scratching intensity, SCR/VAS 
during the last 24 hours. On the back side of the modified Faces Pain Scale was a pre-printed 0-100 
mm VAS scale, and the SCR/VAS score corresponding to the owner’s placement of the horizontal 





The dog’s pain / discomfort intensity was also rated on the numeric rating scale. Assessment of 
PAIN/NRS ranged from 0=no pain/discomfort to 10=worst pain/discomfort imaginable. The above 
described modified Faces Pain Scale was used for the owner’s rating of pain / discomfort, PAIN/VAS. 
Finally, the owner was asked to rate the dog’s QOL as ‘could not be better’, ‘good’, ‘fairly good’, 
‘neither good nor bad’, ‘fairly poor’, ‘poor’, ‘could not be worse’ or ‘do not know’.  
The PI rated the dog’s scratching intensity and pain / discomfort respectively by means of the 
same NRS and VAS-scales as the owner after each visit. In addition, the PI assessed the dog’s 
subjective QOL based on the history, clinical findings and overall subjective impression of clinical 
efficacy of the initiated treatment on number of scratching events and stress level.  
The owners were provided with a diary at enrolment to log deviations of medicine administration 
deviated from the predefined time, the daily scratching intensity, SCR/NRS and to document any 
side effects and other observations during the trial period. The dogs’ body weight was continuously 
recorded during follow-up visits. Additionally, the owners were asked a series of closed and semi-
open questions at each follow-up visit to monitor side effects and adverse events. The questions 
addressed activity level, appetite, aggression, ataxia, behavioral changes, fecal score, food intake, 
somnolence, vomiting, water intake and details on their dog’s scratching phenotype.  
To account for end-of-trial owner-compliance, the remaining number of capsules were counted 
at each follow-up visit. The proportion of capsules given relative to the expected number of capsules 
given at each follow-up visit was used to categorise owners as ‘satisfactory adherent’ (³ 90% 
capsules administered correctly) or ‘suboptimal administrator’ (³ 80% and ≤ 90% capsules 
administered correctly) (Pullar et al. 1989; Dodd et al. 2012). At the last follow-up visit owners were 
asked for a final preference statement (treatment period one or two). 
 
Statistical analysis 
Data were analysed with SAS Studio 3.71 (SAS Institute Inc.; NC, USA). P < 0.05 was considered 
significant. Descriptive statistics for categorial variables are reported by frequencies and 
proportions and for continuous data as medians and ranges except for the primary outcome 
‘number of scratching events’ which is reported as mean and range. Since ‘number of scratching 
events’ is a count variable, a negative Binomial distribution was used to model it, allowing for 





period, follow-up visit number and potential carryover was modelled using a log-link (i.e. 
multiplicative effects), and a generalised estimating equation was applied to account for the 
correlation of scratching events over time for the same dog (Zeger & Liang 1986). The effect 
estimates are given as ratios, e.g. of PGN vs. placebo. Treatment effect on owner and PI-assessed 
secondary outcomes SCR/NRS, SCR/VAS, PAIN/ NRS and PAIN/VAS was modelled by means of a 
general linear mixed model as was the effect on body weight after log-transformation (Liang & Zeger 
1986). Cross-tabulations were made to assess the agreement between owners and the PI with 
regard to the dogs’ QOL. Data were included in the analysis when dogs had participated in at least 
three of four consecutive follow-up visits. If owners answered a question with ‘do not know’, data 
were excluded from analysis.  
 
Results 
81 potential cases were consecutively assessed for eligibility between March 2017 and June 2018 
(see trial profile, Figure 2). Seventeen eligible dogs underwent pre-inclusion visits. Four of these 
were excluded (due to severe proprioceptive deficits, aberrant, obsessive compulsive behaviour, 
lack of owner compliance and one dog only scratched during oestrus). The thirteen remaining dogs 
were consecutively included in the study from April 2017 to June 2018 and randomised to treatment 
arm A (n=5) or B (n=8) after baseline data collection. The last follow-up visit took place in July 2018. 
Eleven dogs completed the trial. One dog was excluded after follow-up I due to non-compliance to 
the protocol and is therefore not included in the reported results, and one dog was withdrawn by 
the owner after follow-up III due to ataxia and somnolence. No dogs needed rescue analgesics 
during the trial.  
At baseline, the 12 participants (six females, one neutered female, four males and one castrated 
male) had a median age of 3.6 years (1.1 - 7.4), a median bodyweight of 8.7 kg (8.2 - 10.8) and a 
median NeP-score of 1.1 (0.7 - 2.6). The overall mean number of scratching events during ten 
minutes of continuous physical activity was 9.1 (2 - 27). Additional information including MRI 






The treatment effect of PGN on the mean number of scratching events was estimated to be a factor 
0.16 (CI95 = 0.11, 0.25) corresponding to an 84% reduction from baseline in the mean number of 
scratching events during ten minutes of continuous physical activity when compared to placebo (P 
= <0.0001, see Figure 3). No significant effects of neither placebo, period, follow-up visit number 
nor carryover was seen. 
Efficacy estimates of PGN on secondary outcomes showed a significant reduction from baseline 
in owner-reported mean scratching and pain intensities on both the numeric rating scale (SCR/NRS 
of -2.7 (P = 0.003)) and the modified Faces Pain Scale (SCR/VAS of -33 (P > 0.0001) and PAIN/VAS of 
-24 (P=0.01)). The same significant effect of PGN on PI-assessed secondary outcomes was seen, 
since the mean SCR/NRS was reduced by -2.7 (P=0.0016), SCR/VAS by -29 (P=0.001), PAIN/NRS by -
4.1 (P<0.0001) and PAIN/VAS by -44 (P<0.0001). The only exception, where no difference was seen 
in effect between PGN and placebo, was on owner-assessed PAIN/NRS (P=0.056). The efficacy 
estimates’ confidence limits are reported in Table 2.  
 
Additional information reported by the owners  
According to the owners’ diary records, the clinical effect of PGN was observable 48-72 hours after 
the PGN administration was initiated. Hereafter, the dogs were not scratching for consecutive days 
at home during the PGN-treatment period. The scratching profile changed during treatment with 
PGN: the phantom scratch stopped in seven of eight dogs and vocalisation when scratching ceased 
in five dogs (100%).  
External factors that affected the owners’ daily SCR/NRS ratings were: wearing a harness or a 
collar in six of the included dogs, flea infestation, which was promptly treated in two of the included 
cases in arm B during treatment period two, and increased scratching intensities during oestrus was 
reported in two females during the trial. Three dogs were initially reluctant to take medications and 
four owners found it difficult to fit the 12-hours dosing intervals into their daily routines. 
 
Side effects and adverse events 
The prevalence of owner-reported side effects and adverse events continuously registered at each 
follow-up visit is presented in Table 3. The most prevalent side effects following PGN administration 






9/12 dogs. The body weight of included dogs ranged from 8.0 kg to 11.4 kg during the trial. The 
resulting administered dose range was 13 - 19 mg/kg q 12 h. Overall, this dose of PGN was well 
tolerated in all but the one dog, that was withdrawn by the owner due to ataxia as previously 
described. Despite the reported increase in appetite and a clinical overt weight gain in four dogs, 
the overall increase in the dogs’ mean bodyweight of 2.1 % (CI95 = 0.4%, 4.6%) during PGN treatment 
was non-significant (P < 0.099). The weight gain was more evident in four ad-lib fed dogs compared 
to the other seven dogs whose owners were more attentive to restricted feeding. No adverse events 
were seen during the trial.  
 
Quality of life 
The owner-assessed QOL improved in 38% of dogs allocated to arm A (PGN - placebo) and in 36% 
of the cases allocated to arm B (placebo - PGN) during treatment with PGN relative to baseline 
assessment. During the placebo-period, the owner-assessed QOL improved in 25% of the dogs in 
arm A whereas none of the owners reported improved QOL during placebo treatment for dogs 
allocated to arm B. A cross-tabulated comparison of the overall agreement between the owner and 
PI-assessed QOL revealed agreement in 30/58 assessments. In 21 of the remaining 28 cases, the 
owner evaluated a better QOL, which was significantly more often than the PI (P=0.016).  
 
Compliance 
The overall owner compliance (number of capsules administered relative to the number of capsules 
expected to be administered) was 98% (range 93% - 105%). One owner had forgotten to up-titrate 
during treatment period two. Consequently, the duration of treatment period two was only 24 days, 
which results in the “over-compliance” of 105% (46 capsules administered in 44 days). All owners in 
treatment arm B and two owners in treatment arm A (50%) were categorised as ‘satisfactory 
adherent’ (> 90% capsules administered correctly) at all 4 follow-up visits. Two treatment arm A-
owners (50%), were categorised as ‘suboptimal administrators’ (³ 80% but ≤ 90% capsules 
administered correctly) during the placebo-period.  
 




To assess the efficacy of blinding, owners were asked for a final preference statement at the end-
of-trial visit. Despite blinding to treatment allocation and the reported side effects, all 12 owners 
preferred the period in which their dog had received PGN over the placebo-period.  
 
Discussion 
The present randomised controlled trial provides convincing evidence that PGN significantly 
alleviates clinical signs of SM-related CNeP in CKCS. The estimated treatment effect of PGN was a 
reduction of 84% in the mean number of scratching events relative to baseline. However, the 
relatively wide confidence interval of 75% - 89% indicates some clinical variation in the response 
between dogs. In addition, PGN significantly reduced the owner- and PI-assessed NRS and VAS 
scratching- and VAS pain intensities and improved QOL in all the included dogs. To the authors’ 
knowledge this is the first evidence-based treatment recommendation to reduce clinical signs of 
SM-related CNeP. The analgesic effect of another human-labelled GABA-analogue, gabapentin has 
been found non-significant in dogs with postoperative and bone cancer pain (Wagner et al. 2010; 
Aghighi et al. 2012; Crociolli et al. 2015; Monteiro et al. 2018). A single-blinded trial of gabapentin 
as an add-on to carprofen in CKCS with clinical signs of SM reported a significant improvement in 
QOL as an indirect indicator of pain alleviation compared to baseline (Plessas et al. 2015). The 
authors speculated, if insufficient dose rationales can explain the non-significant effect in the 
previous studies rather than a veritable lack of effect.  
The primary outcome definition ‘number of scratching events during 10 minutes of continuous 
observation’ was based on previous reports on the most prevalent clinical signs in CKCS with SM 
(Rusbridge et al. 2000; Rusbridge et al. 2007; Sanchis-Mora et al. 2016; Sparks et al. 2018). As 
scratching is a common, daily observed behaviour in dogs, the authors acknowledge that not all 
types of scratching in CKCS can be ascribed to the SM-related parenchymal spinal cord changes 
alone. Consequently, dogs were excluded if their scratch was solely directed at the ears or face. This 
very strict inclusion of cases served to avoid the potential confounding effects of Chiari-like 
malformation and otitis media with effusion as primary causes of scratching. Overall, a great 
variation in the primary outcome within and between dogs was seen during follow-up visits. 
According to the owners, the dogs’ scratching was more evident at the day of follow-up visits than 




as well as wearing a collar or harness has previously been reported as a cause of scratching 
intensification (Rusbridge et al. 2000; Rutherford et al. 2012). Transportation, often by car, entering 
the hospital facility and wearing a collar or harness during video recordings, flea infestation and 
oestrus were all confounding factors that most likely contributed to this variation and the resulting 
relatively broad confidence interval of the primary outcome. Ectoparasite prophylaxis was initiated 
in all dogs at inclusion. Repeated prophylactic treatment when indicated was not incorporated in 
the protocol which explain the unfortunate flea infestation towards the end of trial period two.  
The trial was designed to mimic the clinical setting to document the real-life effect of PGN. For 
that reason, we deselected a run-in period. Although the overall owner compliance was very good, 
variations within and between owners and dogs that could affect the primary outcome measure 
were seen: initial reluctance among dogs to accept PO administration of PGN and fluctuations in the 
owners’ daily routines not always compatible with the 12 h dosing interval. The above mentioned 
physiological, environmental and practical factors are difficult to control for in a clinical trial but the 
nature of the crossover design reduces the impact on the overall conclusions. 
The benefit-risk profile assessment indicates, that PGN is safe and well tolerated in the applied 
regimen of 13 - 19 mg/kg q 12 h. The most prevalent entailed side effects were an increase in 
appetite, a resultant increase in body weight in ad-lib fed dogs and transient ataxia of less than ten 
days duration. The latter was subjectively described by the owners as acceptable and resolved 
within one to ten days. Only one owner assessed that side effects exceeded benefits in the reduction 
of clinical signs and withdrew the dog from the study. Based on the reported possible side effects 
listed in PGNs’ summary of product characteristics (Lyrica SPC)(Lyrica SPC), the side effects reported 
in the present study were to be expected. No placebo effects could be identified during the data-
analysis. Interestingly, three owners reported potential nocebo-effects during the placebo-period: 
polyphagia in two dogs and ataxia in one dog, that could not be confirmed on clinical examination. 
A major advantage of PGN treatment which was described by all owners was an improved QOL.  
In conclusion, this is the first independent, authority-approved controlled clinical trial that 
reports a significant reduction in SM related clinical signs of CNeP and improved QOL in client-
owned CKCS. Based on our results, we provide an effective and safe evidence-based treatment 
recommendation of PGN 13 - 19 mg/kg q 12 h. Furthermore, the present study enables future 





SM related clinical signs of CNeP. This short-term study proves treatment effect, but to assess if 
chronic administration of PGN in dogs is safe, a longitudinal cohort study with continuous 
monitoring of effective plasma PGN concentration and potential adverse effects on organ systems 
is needed. Finally, before treatment is initiated in the clinical setting, an important distinction 
between statistical significance and the clinically relevant treatment efficacy must be 
communicated to owners. It must be emphasised that monotherapy with PGN will alleviate the 
dog’s clinical signs significantly without being a remedy for the underlying, progressive spinal 
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Table 1   Baseline characteristics.  
Baseline characteristics of the 12 Cavalier King Charles Spaniels included in the trial data analysis. 
Continuous variables are reported as median (range) except for the primary outcome ‘number of 




F, female; FN, female neutered; M, male; MN, male neutered. NeP score, neuropathic pain score. 
NRS, numeric rating scale. OME, otitis media with effusion - a tentative MRI diagnosis based on T2 
hyperintense material in the tympanic bullae. Syrinx : spinal cord ratio, ratio of diameters measured 
where the syrinx was widest on T1-weighted images. VAS, visual analogue scale. VRS, verbal rating 
scale. * One owner was not able to rate the dog’s quality of life.  
Chiari-like malformation (yes / no)
Syrinx : spinal cord ratio 
OME (no / bilateral / unilateral)
Owner-assessed PI-assessed
NRS, 0-10 4 (1 - 7) 6 (1-8)
VAS, 0-100 mm 42 (28 - 65) 62 (12 - 79)
NRS, 0-10 2.7 (0 - 5) 4.5 (2 -8)
VAS, 0-100 mm 35 (0 - 50) 50 (22 - 79)
Could not be better / good / fairly good / 
neither good, nor bad / bad 3 / 4 / 4 / 0 / 0* 0 / 4 / 5 / 2 / 1
6 / 4 / 2
Scratching intensity 
Age (years)







Number of scratching events
MRI characteristics
3.6 (1.1 - 7.4)
6 / 1 / 4 / 1
8.7 (8.2 - 10.8)
1.1 (0.7 - 2.6)
9.1 (2 - 27)
13 / 0




Table 2   Pregabalin’s effect on secondary outcomes.  
Pregabalin’s effect on secondary outcomes was assessed by the owner and the PI. A generalised 
linear mixed model including treatment (pregabalin or placebo), treatment period and follow-up 
visit number was used to estimate the mean treatment effect in treatment period one compared to 
baseline values.  
 
NRS, numeric rating scale. VAS, visual analogue scale.  
 
  
Baseline mean Treatment effect (CI95) P Baseline mean Treatment effect (CI95) P
NRS, 0-10 4.0 - 2.7 (-4.4, -1.0) 0.003 5.2 - 2.7 (-4.2, -1.1) 0.0016
VAS, 0-100 mm 43 - 33 (-46, -19) < 0.0001 53 - 29 (-46, -12) 0.001
NRS, 0-10 2.6 -2.1 (-4.3, 0.05) 0.056 4.2 - 4.1 (-5.6, -2.6) < 0.0001







Table 3   Side effects and adverse events.  
The side effects and adverse events were reported by the owners at a total of 47 follow-up visits, 
hereof 23 visits during treatment with pregabalin due to one dropout and 24 visits during the 
placebo period. The owners were asked a series of closed and semi-open questions addressing 
activity level (normal / reduced / hyperactive), aggression (towards other people / animals, yes / 
no), appetite (normal / increased / decreased), ataxia (yes / no), behavioral changes (yes / no – if 
yes, please describe), fecal score (normal / hard / moist / watery), food intake (normal / increased 
/ decreased), sleeping pattern (normal / reduced sleeping activity / somnolence), vomiting (yes / 
no), water intake (normal / increased / decreased) and details on their dog’s scratching phenotype 
(intensity compared to baseline, anatomical localisation, phantom scratching yes/no) and if the dog 




Reduced 5  4 2  1
Hyperactive 2  2 1  1
0 0
14  9 1  1
1  1 1  1
Hypophagia 1  1 5  4
Polyphagia 18  9 3  2
0 0
1  1 0
0 0
Reduced 0 1  1












Total number of side effects in  








able 3   Sid  effects nd adv rs  events.  
The side effec  and adverse events were r ported by the owners at a total of 7 follow-up visits,
hereof 23 visits during tr atm nt with pregabalin due to one dropout a d 24 visit  during the 
placebo period. The owners were asked a s ries of closed and semi-open questions addressing 
activity l vel reduced / hype active ggression (towards othe  people / animals, yes /
no)  appetite (normal / increased / decreased), ataxia (yes / no), behavior l changes (yes / no – if 
yes, pl as  de cribe), fecal score (normal / hard / moist / w tery), food intake (normal / i creased
/ decreased), sleeping p ttern (normal / reduc  sleeping activity / somnolence), vomiting (yes / 
no), wa er intake (norm l / incre sed / decreased) and details n their dog’s scratching phenotype
(intensity compared to baseline, anatomical localisation, phantom scratching yes/no) and if the dog 




Reduced 5  4 2  
Hyperactive 2  2 1  1
0 0
14  9   
1  1 1  1
Hypophagia 1  1 5  4




Reduced 0   










Total number of side effects in  












Trial design   The trial was designed as a two-treatment two-period crossover study. Eligible Cavalier 
King Charles Spaniels expressing clinical signs consistent with SM-related central neuropathic pain 
were randomised to treatment arm A (treatment sequence pregabalin - placebo) or treatment arm 
B (placebo - pregabalin) after baseline data collection. Each treatment period was of 25 days 
duration separate by a 48-hour washout period. During the dose escalation and taper phase, 150 
mg of pregabalin was administered q 24 hours. In the fixed dose treatment phase, 150 pregabalin 
was administered q 12 hours. Primary and secondary outcomes were assessed at baseline collection 











DOSE ESCALATION PHASE 
Pregabalin 150 mg q 24 hours
DAY 1-2 DOSE ESCALATION PHASE 
Placebo 1 capsule q 24 hours
FIXED DOSE TREATMENT PHASE
Pregabalin 150 mg q 12 hours
DAY 3-23 FIXED DOSE PLACEBO PHASE
Placebo 1 capsule q 12 hours
FOLLOW-UP VISIT I DAY 7 (+/-2)
FOLLOW-UP VISIT II DAY 21 (+/-2)
TAPER PHASE
Pregabalin 150 mg q 24 hours
DAY 24-25 TAPER PHASE
Placebo 1 capsule q 24 hours
WASHOUT PERIOD
48 HOURS 
DAY 26-27 WASHOUT PERIOD
48 HOURS
DOSE ESCALATION PHASE 
Placebo 1 capsule q 24 hours
DAY 28-29 DOSE ESCALATION PHASE 
Pregabalin 150 mg q 24 hours
FIXED DOSE PLACEBO PHASE
Placebo 1 capsule q 12 hours
DAY 30-50 FIXED DOSE TREATMENT PHASE
Pregabalin 150 mg q 12 hours
FOLLOW-UP VISIT III DAY 34 (+/-2)
FOLLOW-UP VISIT IV DAY 48 (+/-2)
TAPER PHASE
Placebo 1 capsule q 24 hours
DAY 51-52 TAPER PHASE








Trial profile   Recruitment was initiated in January 2017. Overall, 81 owners and veterinarians 
responded to the recruitment notices. Of the 81 enquiries, seventeen potential cases (21%) were 
continuously enrolled in pre-inclusion visits, and 13 dogs were included in the study between March 







Pregabalin’s effect on the clinical signs of central neuropathic pain in dogs with syringomyelia   
The number of scratching events during ten minutes of continuous, physical activity was quantified 
after video documentation at baseline and follow-up visits. Included dogs were allocated to 
treatment arm A (treatment sequence pregabalin - placebo) and treatment arm B (treatment 
sequence placebo - pregabalin) after visit 1 (pre-inclusion visit). Visit 2 and 3 on the x-axis refers to 
follow-up visits in treatment period one, and visit 4 and 5 refers to follow-up visits in treatment 
period two. The two treatment periods were separated by a 48-hour washout period.   



























day 1 - 25
Treatment period 2:
day 28 - 52
Washout period: 48 hoursPre-inclusion visit and 
baseline data collection
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